1	Discovery of a novel antibiotic, Transitmycin, from <i>Streptomyces</i> sp unveils
2	highly efficient activities against tuberculosis and human
3	immunodeficiency virus
4	Vanaja Kumar <sup>*1,4</sup> , Balagurunathan Ramasamy <sup>2</sup> , Mukesh Doble <sup>\$3,5</sup> , Radhakrishnan
5	Manikkam <sup>4</sup> , Luke Elizabeth Hanna <sup>1</sup> , Gandarvakottai Senthilkumar Arumugam <sup>3,7</sup> , Kannan
6	Damodharan <sup>3</sup> , Suresh Ganesan <sup>3</sup> , Azger Dusthakeer <sup>1</sup> , Precilla Lucia <sup>1</sup> , Shainaba A Saadhali <sup>1</sup> ,
7	Shanthi John <sup>2</sup> , Poongothai Eswaran <sup>2</sup> , Selvakumar Nagamiah <sup>1</sup> , Jaleel UCA <sup>6</sup> , Rakhila M <sup>6</sup> ,
8	Ayisha Safeeda <sup>6</sup> and Sathish S <sup>6</sup>
9	<sup>1</sup> National Institute for Research in Tuberculosis, Chennai – 600031, Tamilnadu, India
10	<sup>2</sup> Department of Microbiology, Periyar University, Salem – 636011, Tamilnadu, India
11	<sup>3</sup> Department of Biotechnology, Indian Institute of Technology, Madras – 600036, Tamilnadu, India
12	<sup>4</sup> Centre for Drug Discovery and Development, Sathyabama Institute of Science and Technology
13	(Deemed to be University), Chennai – 600119, Tamilnadu. India
14	<sup>5</sup> Saveetha Dental College and Hospitals, 62, Poonamallee High Rd, Chennai, 600077, India
15	<sup>6</sup> Open Source Pharma Foundation-National Institute of Advanced Studies Drug Discovery Lab, NIAS, IISc
16	Campus, Bangalore, Karnataka, India
17	<sup>7</sup> SSS International Drug Discovery & Development Research Private Limited, Innovation & Entrepreneurship,
18	Sudha & Shankar innovation hub, IIT Madras, Chennai-600036, India
19	Email: * <u>vanaja_kumar51@yahoo.co.in;</u> * mukeshdoble.sdc@saveetha.com
20	Abstract
21	

22 HIV is identified as a factor that aggravates tuberculosis disease pathogenesis and its 23 progression to latent TB. While, TB is declared as one of the major causes for AIDS-24 associated mortality. So there is a dire need for new drugs to combat such ailments that have a synergistic interaction. This has led us to study a novel antibiotic purified from a marine 25 26 Streptomyces sp isolated from the coral reef ecosystem of South Indian coast. Streptomyces 27 sp. R2 (MTCC 5597; DSM 26035)., isolated from the marine water was grown on agar plates 28 and the crude yellowish orange pigment secreted was extracted using various solvents. The 29 antibiotic, named as Transitmycin, was purified and tested against M. tuberculosis, drug 30 resistant strains, and M. tuberculosis biofilm. The compound was also tested against HIV-1 31 viruses belonging to six subtypes. Several characterisation tools were used to elucidate the 32 structure of this novel antibiotic. Transitmycin was derivitaised to elucidate the absolute configurations of the amino acids present in it. Tr, unlike actinomycin D, has L-valine in both 33 34 the rings instead of D-valine (found in the latter). Also, one of the proline in Tr is in D-35 NATE guisation while it was and bound and a second and the second

36 compound and is not reported so far. It exhibits dual activities against the standard H37Rv, 37 49 drug sensitive clinical isolates, and MtB biofilm as well as standard and 20 clinical 38 isolates of HIV. This is the first paper that reports the isolation of a new antibiotic from 39 marine actinobacteria exhibiting unusual anti-TB and HIV activities which could be exploited 40 further as a lead molecule in the quest for the design of drug with dual activities.

- 41
- 42 Highlights

A novel antibiotic was purified from a marine Streptomyces sp isolated from the coral
reef of S. India

Presence of L-valine, not observed in actinomycin D, and one of the proline in D
 configuration suggest that it is a novel structure not reported before

47 • It exhibits activity against standard MtB strain as well as clinical isolates and drug
48 resistance ones

49 • It exhibits anti-HIV activity against several clinical isolates

50 Key words: Antibiotic, *Streptomyces* sp., Actinomycin, Transitmycin, Tuberculosis, HIV,

51

# 52 Introduction

53 Despite, the history of infectious diseases is time immemorial, an urgent need for protection 54 against infectious diseases has one of the major health concerns. Antibiotics have 55 revolutionized the diagnostic factor in various aspects and the drug discovery is considered as 56 a hallmark in human history. However, the concomitant development of resistance against 57 diseases is the most serious consequence [1]. In 2020, an overall rate of 1.5 million people pretentious from TB. In fact, TB is one of the leading sources of death, wherein occupied the 58 59 13<sup>th</sup> position and moreover the second foremost infective destroyer after COVID-19 (above 60 HIV/AIDS). Since it is an airborne infectious disease caused by *M tuberculosis*, continues to 61 be a major cause of mortality and morbidity worldwide [2].

62 An upsurge of multi drug resistance (MDR) and extensively drug resistance (XDR) is 63 an additional perturbing factor in tuberculosis chemotherapy. Comprehensively, the existing 64 treatment for TB based on half yearly quadruple therapy containing rifampicin, isoniazid, ethambutol and pyrazinamide results the cure rate of 90-95% [3] for drug-sensitive TB at 65 global level. Nevertheless, this regimen is inadequate to treat MDR and XDR-TB infections, 66 67 sometimes the second line antibiotics are employed to treat MDR-TB infections for prolonged time whereas XDR infections are almost untreatable. Different TB drugs with 68 69 unique mode of action are desperately necessary to fight against drug resistant tuberculosis.

70 For example, bedaquiline and delamanid are approved for drug resistant TB, however due to 71 the reported toxicity issues, they may employ only on last resort [4]. In addition, the second 72 line drugs used to treat MDR-TB with several disadvantages such as less efficacious, more 73 toxic, and more expensive than the first-line drugs [5]. At presently progressing anti TB drugs 74 should partake essential properties like succeed a short therapy period (sterilizing effect), a 75 simpler regimen, capable of act on MDR/XDR-TB, concurrent treatment of TB/HIV and 76 advanced safety level than the existing drugs [6]. Alike the human immunodeficiency virus 77 (HIV) leads to destruction of the immune system resulting a condition termed as Acquired 78 Immuno Deficiency Syndrome (AIDS). After its finding AIDS becomes a great risk to 79 humans, reflected to be pandemic and it is the greatest public health crisis in globally. As of 80 2021, millions of people living with HIV were rescuing antiretroviral therapy [7]. Several 81 researches have been developed the drugs against HIV disease, such as the growth of many 82 antiretroviral drugs (ARVs), including the atazanavir, ibalizumab, darunavir, abacavir, 83 zidovudine, lamivudine, efavirenz, tenofovir disoproxil fumarate, tenofovir alafenamide, 84 emtricitabine, bictegravir, cabotegravir, rilpivirine etc. nevertheless, the competency of HIV 85 intensive to mutate rapidly leads to the upsurge of drug resistance to existing anti-retrovirals 86 [8]. Since the finding of penicillin, many of the microbial natural products tends to the new 87 paradigm for novel drug discovery development [9,10].

88 Over the past 60 years, [11] the microbial bioprospecting has gained a remarkable 89 quantity of medicinal components, including actinobacteria, the major bacterial phylum 90 group of Gram-positive bacteria with guanine and cytosine (G+C) rich content in their 91 genomic sequence, which are the important prokaryotes in economic and ecological manner. 92 Significantly the existence of actinobacterial multiplicity in several rare ecosystems liable for 93 prolific producers of many biologically active natural compounds with different potential 94 activities [12-15]. Some of the pharmaceutical companies have dramatically declined in the 95 result of novel wide range antibiotics in the past few decades [16]. Obviously, this critical 96 state has caused in the surplus of such antibiotics with distinct mode of activity targeting the 97 arcade, wherein this precluded the assessment of usual terrestrial sources in particular for 98 actinobacteria and led scientists to pursuit unique habitats on the marine family for novel bioactive molecules [12,17,18]. Indeed, actinobacteria are ubiquitous in the marine 99 100 environment, which are occupying a substantial ecological characteristic in the recycling and 101 production of novel natural products with huge pharmaceutical applications [19].

102 Generally, the 16S rRNA gene sequencing has concomitantly employed to identify,103 classify and quantitation of microbes in multifaceted biological molecules. It is obvious from

104 the 16S rRNA sequencing that marine microbial species as bacteria and archae have an 105 extreme different taxonomy. Even the 16S rRNA sequences of more than ten thousand 106 actinomycetes had been isolated hitherto from marine outsources. The discovery of novel 107 secondary metabolites from marine actinobacteria has just surpassed that of their terrestrial 108 counterparts [15]. According to the review of Blunt et al., [20] shown that there are 179 new 109 natural products isolated during 2016, in which the actinobacterial genus Streptomyces 110 remains to be the dominant source. An extensive study on typical marine actinobacterial 111 genera like Salinispora and Verrucosispora produces salinosporamide and abyssomycin 112 respectively, which suggest that actinobacteria improves significant feature towards marine 113 drug discovery research [21]. Further, marine based antibiotics are more ingenious in combat 114 infections due to the terrestrial bacteria do not have chance to develop resistance against them 115 [22]. During the microbial bioprospecting process, the actinobacterial extracts isolated from 116 various less-explored ecosystems were screened for anti-TB and anti-HIV activity. The isolation, characterization and potential bioactivities against TB and HIV of an antibiotic 117 118 obtained from a marine *Streptomyces* sp. R2 is being reported herewith.

119

#### 120 Results and Discussion

#### 121 Description of the actinobacterial strain

122 Transitmycin is a depsipeptide (bicyclic) molecule produced by actinobacterial strain R2, 123 which was isolated from the sediment samples from Rameswaram coral reef ecosystem (Lat. 9.2876° N; Long. 79.3129° E), Tamil Nadu, South India using Starch Casein Agar (SCA) 124 125 supplemented with nalidixic acid (20µg/ml) and nystatin (100µg/ml). Viability of strain was 126 maintained in International Streptomyces Project-2 (ISP2) agar slants, 30% glycerol broth 127 followed by lyophilisation. It was also deposited in Microbial Type Culture Collection 128 (MTCC), India and in DSMZ – German Collection of Microorganisms and Cell Cultures, 129 Germany. (R2 = MTCC5597; DSM26035).

#### **130** Characterization and taxonomy

The characterization of a strain is the key element in classification of prokaryotes including actinobacteria [23]. Actinobacterial classification was initially based mainly on morphological and physiological characteristics [24-25]. The onset of chemotaxonomic standards has provided reproducible and reliable data to identify the genera at genus level [26]. This microbial strain R2 under microscopic observation showed the presence of dense aerial and substrate mycelia with long, un-fragmented spore chains with hairy structures (Supplementary Fig. 1a-b). The physiological and biochemical characteristics of the strain R2

138 are given in Supplementary S-Table 1. Strain R2 showed good growth in various ISP media 139 and utilized a wide range of carbon and nitrogen sources. In addition, good growth was also 140 observed at different physiological conditions. Notably, the extracellular vellow pigment 141 production was greatly influenced by nitrogen substrates, pH, temperature and NaCl. Strain 142 R2 produced lipase and amylase. High sensitivity was observed for most of the antibiotics tested (Supplementary S-Table 1). The cell wall analysis revealed that the strain R2 is rich in 143 144 LL-2,6-Diaminopimelic acid (L-DAP) and glycine. No diagnostic sugars were found in the 145 cell wall constituents. In our present study, the results of phenotypic characterization and cell 146 wall analysis indicated that the actinobacterial strain R2 belongs to the genus *Streptomyces*, 147 however it is not adequate for differentiation at species level.

Furthermore, the PCR (Polymerase Chain Reaction) amplification of 16S rRNA gene of strain R2 formed around 1400 base pair sequence and the BLAST (Basic Local Alignment Search Tool) analysis have shown 99% similarity to the 16S rRNA gene sequence of *Streptomyces variabilis* (EU570414) and other closely related species submitted in GenBank. Phylogenetic relationship of the strain R2 and related taxa are given in Supplementary S-Fig. 1c.

154

155 The 16S rRNA gene sequence of strain R2 has the accession number HQ012501at GenBank, 156 but this gene provides limited resolution for species level identification, since it discloses 157 more extensive genotypic differences. At this stage, the average nucleotide identity (ANI) 158 [27] of all preserved genes between any two genomes shows likely to reform taxonomy, 159 because it also correlates with the best DNA: DNA Hybridization (DDH) values. The most 160 often used standards for species delineation *i.e.* the 70% DDH [28] which is closely 161 equivalent to 95% ANI (Average Nucleotide Identity) values. Moreover, no organisms have 162 been defined hitherto has shown <98.7% identity in their 16s rRNA gene and shown <95% 163 ANI or 70% DDH. These results supported the substitution of cumbersome DDH and related 164 procedures with simple sequence-based standards. Significantly the metabolic property of 165 transitmycin production had not been reported before from any other meticulously associated 166 Streptomyces species. Based on the aforesaid facts, the actinobacterial strain R2 is identified 167 to be a novel strain of Streptomyces variabilis, but still it showed 99% similarity with its 168 associated proximity neighbors. It is very important to mention here that there is no literature 169 evidence on any commercially available antibiotic, in particular anti-TB and/or anti-HIV 170 compounds from Streptomyces variabilis.

**171** *Transitmycin production* 

The growth of *Streptomyces* sp. R2 is simultaneously observed with grey colour aerial mycelia and soluble yellow orange pigment in good yield. The crude compound is extracted well in several solvents namely, methanol, chloroform and dichloromethane, followed by diethyl ether and ethyl acetate (Supplementary Table 2). The extracts in the former solvents were intensely coloured when compared to the extracts from the latter solvents. Salts and debris were present in the extracts while using former solvents, so ultimately ethyl acetate was chosen for extracting the bioactive pigment.

179 The activity of the crude extract was also tested on different strains of *M. tuberculosis*. More 180 than 95% reduction in Relative Light Units (RLU) was observed through Luciferase Reporter 181 Phage Assay against all three *M. tuberculosis* strains. When 1.0 L of YEME agar was used 182 for production it yielded 800 mg crude antibiotic extract in ethyl acetate. Major antibiotics reported from actinobacteria are extracellular in nature [29-30]. Industrial production of many 183 184 antibiotics from Streptomyces is achieved through submerged fermentation process [31]. In 185 contrast, some actinobacterial strains are found to produce antibiotics only on solid media and 186 very little reason is reporeted as to why activity is restricted to solid culture and not observed 187 in submerged cultures. Shomura et al reported [32] that about 1300 out of 6500 188 actinomycetes showed antimicrobial activity against one or more of the test organisms when 189 tested by agar plug method. In the secondary screening, about 25 (1.9%) of the 1300 strains 190 were found to be non-producers in submerged cultures. So, we conlcude that the reports of 191 antibiotics isolated from only agar cultures of actinomycetes are very rare.

192 According to Mayurama *et al.* [33] fumaridamycin was detected with much difficulty 193 in submerged cultures, because the mycelium of the producing strain inactivate the antibiotic 194 more readily in liquid than in agar culture. Similarly, Shomuraet al [32] demonstrated that the 195 antibiotic produced by Streptomyces halstedii has shown activity against Gram negative 196 bacteria only in agar dishes, which correlates well with its mycelial morphology. The aerial 197 mycelium was filamentous during antibiotic production in solid cultures, but fragmented in 198 non-producing liquid cultures. Similar to report from Shomura et al. [32] the bioactive 199 pigment production by the Streptomyces strain R2 was observed only in agar culture, where 200 the vegetative mycelium was filamentous. While decreasing the concentration of YEME 201 broth from 2X to 1/10X the mycelia filamentation was found to increase. However, none of 202 the five concentrations of YEME broth produced the pigment (unpublished data). This 203 outcome evidenced that the filamentous mycelial structure does not influence pigment 204 production by the strain R2 in broth while the bioactive pigment production was observed in 205 all the concentrations of YEME agar when filamentous mycelia was formed. In accordance to

Ohnishi *et al.* [34] who reported that 2-aminophenoxazin-3-one containing grixazone A and B, afford yellow pigments during phosphate depletion by *Streptomyces griseus*. By adopting these strategies, it was concluded that optimizing the medium components may trigger the pigmented bioactive compound production by our isolated *Streptomyces* sp. R2 in liquid cultures.

211

# 212 Transitmycin purification, characterization and structure elucidation

213

The *Streptomyces* sp. R2 was found to produce 800 mg of crude pigment per litre of yeast extract malt extract medium in agar surface fermentation. The yellow-orange pigment was separated from the crude ethyl acetate extract by TLC and column chromatography and its purity was confirmed by HPLC analysis (Supplementary Fig S13-S17).

Primarily the three well separated spots viz. R1, R2 and R3 with Rf values of 0.8, 0.6, 0.3, 218 respectively were observed on analytical TLC using EtOAc:MeOH (9.5:0.5) solvent system. 219 220 In bioassay directed isolation, fraction R1 (named as Transitmycin) showed more than 95% 221 inhibition against *M. tuberculosis* strain H37Rv in LRP assay. It was isolated as an orange colour amorphous powder with  $[\alpha]_D^{25}$ : -106° (c = 0.2, MeOH). The R1, R2, R3 in crude 222 223 extract and as purified compounds R1, R2, R3 showed similar retention time in RP-HPLC 224 chromatograph (Fig, 1a-d). A single peak of transitmycin at a RT of 5.8 minutes confirmed 225 its purity (Fig. 1c).



226

Fig. 1. Representative HPLC chromatogram of crude and isolated samples R1, R2 and R3. a
RP HPLC of Chromatogram of crude extract of *Streptomyces* sp. R2. b RP HPLC analysis of
mixture of R1, R2, R3. C RP HPLC of Chromatogram of pure Transitmycin R1. d
Transitmycin R1 obtained after column chromatographic purification. e UV-Vis spectra of
Transitmycin R1, R2 and R3. f IR Spectrum of Transitmycin R1.

232 The chemical structures of these molecules (R1, R2 and R3) were elucidated by UV-Visible, IR, CD, <sup>1</sup>H, <sup>13</sup>C, DEPT 135 NMR, 2D NMR (<sup>1</sup>H-<sup>1</sup>H COSY, <sup>1</sup>H-<sup>1</sup>H DQF-COSY, <sup>1</sup>H-<sup>1</sup>H 233 <sup>1</sup>H-<sup>13</sup>C HSQC, <sup>1</sup>H-<sup>13</sup>C HMBC, NOSEY, ROESY) and MALDI-TOF-MS, HR-234 TOCSY, 235 ESIMS, HR-EIMS, HR-LCMS, and 3200 QTRAP-LC/MS/MS analyses and also compared 236 with the previously reported NMR and Mass data of actinomycins (Supplementary 237 Information) [35-57]. Advances in spectroscopic techniques have mainly utilized for 238 compound identification and immensely accelerated the unambiguous representation of compound characterization and structural elucidations. The UV-Vis spectrum of 239 240 Transitmycin showed a strong absorption band around ( $\lambda_{max}$  214, 240, 425, 442 nm (in MeOH) (Fig. 1e). The colour and absorption peak in UV-Vis analysis revealed the presence 241 242 of phenoxazinone chromophore. Singh et al. [58] and Maskey et al. [59] detected the presence of phenoxazinone chromophore in bioactive metabolites from Streptomyces sp. and 243 244 Actinomadura sp. The absolute configuration of the amino acids were supposed to be 245 identical to that of actinomycin D, as indicated by the negative optical rotation values and the 246 strong cotton effect at about 210 nm in the CD spectra. The CD values of Transitmycin (R1) 247 are: [MeOH, [nm], (mdeg)]  $\lambda_{max}(\Delta \epsilon)$  195 (+24.0), 210 (-21.5), 241 (+1.7).

248 In the IR spectrum, a strong absorption broad band appears at around 3435 cm<sup>-1</sup>, an 249 intense strong peak at 1746 cm<sup>-1</sup> and a band around 1099 cm<sup>-1</sup> are assignable to be amino (or 250 hydroxyl), lactone ring and alicyclic 6-membered ether type (C-O) groups, respectively. IR data of transitmycin (R1) (KBr cm<sup>-1</sup>), 3435 cm<sup>-1</sup> for NH, 2958, 2924 cm<sup>-1</sup> (m, -CH str, asvm, 251 252 CH<sub>3</sub> and CH<sub>2</sub>), 2872 cm<sup>-1</sup>, 2853 cm<sup>-1</sup> (m, -CH str, sym, CH<sub>3</sub> and CH<sub>2</sub>),1746 cm<sup>-1</sup> (s, C=O str, lactone ring), 1642 cm<sup>-1</sup>(s, -C=O str, 2° amide), 1524, 1503 (m, -NH bend, 2° amide), 1466 253 (m, CH bend (scissoring), CH<sub>2</sub>), 1379 cm<sup>-1</sup> (s, -CH bend, isopropyl group), 1268 (s, C-O str, 254 255 ester), 1194 (C-O-C of lactone) 1099, 1059, 1017 (s, C-O or C-N), 720, 712, 694, 689 (s, -256 CH bend, oop, aromatic ring), 909 (w, CH<sub>3</sub> rocking) [48] (Fig. 1f).

The <sup>1</sup>H and <sup>13</sup>C NMR spectra exhibited the typical features of two (alpha and beta ring) pentapeptido lactone ring attached with phenoxazinone chromophore, i.e., each ring

259 contained four amide carbonyl resonances and one ester carbonyl in one ring ( $\delta_{\rm C}$  168.8, 173.4, 173.1, 166.2, 167.4 (α-ring) and 168.9, 173.9, 172.7, 166.4, 167.4 (β-ring), together 260 261 with phenoxazinone chromophore (101.8 (C-1), 147.3 (C-2), 179.0 (C-3), 113.4 (C-4), 144.9 262 (C-4a), 140.3 (C-5a), 127.6 (C-6), 130.2 (C-7), 126.0 (C-8), 132.1(C-9), 128.4 (C-9a), 14.9 263 (C-11), 7.6 (C-12), 166.0 (C-13), 165.8 C-14). One of the amino acid proline in the β-ring contained a keto group (208.0 in the <sup>13</sup>C NMR). From <sup>1</sup>H NMR spectrum, NH of amino acids 264 265 (δ<sub>H</sub> 8.23, β-L-Valine), (δ<sub>H</sub> 7.74, α-L-Valine), (δ<sub>H</sub> 7.69, β-L-Threonine, (δ<sub>H</sub> 7.2, α-L-Threonine), ( $\delta_{\rm H}$  6.55, 2H of  $\beta$ -proline) ( $\delta_{\rm H}$  5.93 2H of  $\alpha$ -proline) and four N-methyl groups 266  $(\delta_{\rm H} 2.91, 2.88, 2.89, 2.87)$  (Fig. 2 a-d). In addition, the <sup>1</sup>H NMR spectra of Transitmycin 267 268 indicated the presence of eight methyl groups arising from four isopropyls.



NOTABLE CHARACTERISTIC <sup>1</sup>H NMR SPECTRA OF DIFFERENT PROLINE UNITS OF TRANSITMYCIN (R1), R2, R3

269

Fig. 2 Notable characteristic <sup>1</sup>H NMR spectra of different proline units of Transitmycin as
a R1 (4-oxoproline). b R2 (proline) and c R3 (4-OH proline). d Comparative studies for <sup>1</sup>H
NMR (500 MHz, CDCl<sub>3</sub>) chemical shift value of NH containing amino acid residue and
chromophore motifs of Transitmycin (R1), R2 and R3.

The UV/Vis absorption spectra with maximal absorbance at 240 nm and 442 nm support the presence of an amino phenoxazinone chromophore in its structure. From <sup>1</sup>H - <sup>1</sup>H COSY and TOCSY experiments, five amino acid systems namely Pro, Thr, Val, N-Methyl Val, and Sar were identified. The assignments of the protonated carbons were obtained from the HSQC spectrum, in combination with inspection of the HMBC spectrum. By comparison of the UV spectrum ( $\lambda_{max}$  442 nm, in MeOH) of Transitmycin with that of actinomycin series ( $\lambda_{max}$  440 nm, in MeOH) (Fig. 1e) it was concluded that the former contained an aminophenoxazinone chromophore residue. In <sup>1</sup>H NMR, two *ortho* coupled protons at 7-H, 8-H;  $\delta_{\rm H}$  7.56 and 7.34 corresponding to 1,2,3,4-tetrasubstituted aromatic ring, and two 3H singlet at  $\delta_{\rm H}$  2.52 (11-CH<sub>3</sub>) and 1.95 (12-CH<sub>3</sub>) of methyl groups in peri-position of the aromatic system were identified. This is the characteristics of phenoxazinone chromophore found in various actinomycins.



Fig. 3. a Key <sup>1</sup>H-<sup>1</sup>H COSY correlation of Transitmycin (R1). b Key <sup>1</sup>H-<sup>1</sup>H TOCSY
correlation of Transitmycin (R1). c Key <sup>1</sup>H-<sup>13</sup>C HMBC connectivity for Transitmycin (R1). c
<sup>1</sup>H-<sup>1</sup>H ROESY correlation of Transitmycin (R1). d Chemical structure of isolated compounds
Transitmycin (R1). e R2. f R3.

290 The result was further confirmed by HMBC correlations between the 7-H ( $\delta_{\rm H}$  7.59) and 8-H ( $\delta_H$  7.34) of the tetra substituted double bond and the carbonyl resonances at  $\delta_C$  166.0. The 291 292 carbonyl carbons of Pro, Thr, Sar, Val, and N-methyl Val, were clearly assigned to ( $\delta_{\rm C}$  179.0, 293 174.0, 173.1, 169.02, 198.8, 167.5, 166.5, 166.56, 166.3, 166.1 and 165.9) on the basis of 294 the observed correlations between carbonyl groups protons of the same amino acid residue in the HMBC spectrum. All the residues were connected on the basis of DQF-COSY, TOCSY, 295 HMBC, ROESY and NOESY correlations (Fig. 3a-c), thus establishing the amino acid 296 sequences and overall constitution. (Supplementary Fig. S14-65, S-Table 5). The detailed 297 analysis of <sup>1</sup>H-<sup>1</sup>H COSY, <sup>1</sup>H-<sup>1</sup>H DOF-COSY, <sup>1</sup>H-<sup>13</sup>C HMBC, and <sup>1</sup>H-<sup>13</sup>C HSOC, <sup>1</sup>H-<sup>1</sup>H 298

TOCSY, <sup>1</sup>H<sup>-1</sup>H NOESY, <sup>1</sup>H<sup>-1</sup>H ROESY NMR spectra [35-51] (Supplementary Information 299 Fig. S14-65, S-Table S5) and MALDI-TOF-MS (Fig. 4a-m and Fig. 5) and HR-ESIMS, HR-300 301 LCMS, ESI-MS, QTRAP LC-MS/MS [52-57] (Fig. 5, S-Table S6), (Supplementary 302 Information Fig. S14-115, S-Table S7a-b) spectral fragmentation pattern revealed ten amino 303 acids in Transitmycin (Fig. 3d), which is identical to those present in actinomycin X2 [35-57] 304 (2 X MeVal, 2 X Thr, 2 X Sar, 2 X Val, proline and ketoproline). OPro was identified by the 305 ketone moiety ( $\delta_{\rm C}$  208.6 ppm) and the altered chemical shifts and coupling patterns of the 306 neighbouring methylene groups (Table 1).

- **Table 1.** <sup>1</sup>H NMR (500 MHz,  $CDCl_3$ )/<sup>13</sup>C NMR (125 MHz,  $CDCl_3$ ) and 2D NMR (500 MHz,
- 308 CDCl<sub>3</sub>) correlation spectral data of Transitmycin (R1)  $^{1}$  H $^{-1}$  H COSY,  $^{1}$ H $^{-1}$ H TOCSY  $^{1}$ H $^{-13}$ C
- 309

# HMBC, <sup>1</sup>H<sup>-1</sup>H ROESY

α- ring	Position	δc	δн	J(Hz)	COSY	TOCSY	HMBC	ROSEY
Thr	1	168.8	-	-	-	-	-	-
	2	54.6	4.60	d , 10.0	3, 4, -NH	3, 4	1, 3, 13	3, 4, 2-Val, Val- NH
	3	74.7	5.13	m	2, 4,- NH	2, 4,	4	2, 4, Val-NH
	4	17.0	1.10	d, 6.5	2, 3	2, 3, -NH	2, 3	2, 3, Val-NH
	NH	-	7.29	d, 7.0	2, 3, 4	2, 3, 4	1, 3, 13	2, 4
L-Val	1	173.4	-	-	-	-	-	-
	2	58.7	3.58	dd, 10.5,6.5	3, 4, 5, - NH	3, 4, 5, -NH	1, 5, 1-Thr	3, 4, 5, 2-Pro
	3	31.7	2.08	m	2, 4, 5	2, 4, 5	2,5	4, 5, 4-Thr
	4	19.0	0.89	d, 7.0	2, 3	2, 3, -NH	2,3,5	2, 3, 5
	5	18.9	1.13	d, 6.5	2, 3	2, 3, -NH	2,3,4	2, 3, 2-Val, Val- NH
	NH	-	7.74	d, 5.5	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5, 2- Thr, 3-Thr
Pro	1	173.1	-	-	-	-	-	-
	2	56.4	5.93	d, 9.5	3a,3b,4a,4b	3a,3b 4a, 4b	3, 4, 5, 1- Val	3a, 3b, 2a-Sar,2b- Sar, Sar-NMe
	3	31.6	2.73 1.84	dd, 17.5,7.0 dd, 19.5, 6.5	3b, 4a, 4b 3a, 4a,	3b, 4a, 4b 3a, 4a,	1, 2, 4 1, 4, 5	3b, 2a-Sar, 2b-Sar 3a, 4a, 4b
	4	23.3	2.26 2.01	d, 16.5 d, 8.0	3a, 3b, 4b 3b, 4a	3a, 3b, 4b 3b, 4a	3, 5 3, 5	4b, 5a, 5b 4a, 5a
	5a 5b	47.8	3.86 3.67	d, 18.5 d, 18.5	3a, 4a, 4b 3a, 4a, 4b	3a, 4a, 4b 3a, 4a, 4b	4, 1-Val	5b
Sar	1	166.2	-	-	-	-	-	-
	2	51.2	2a, 4.70 2b, 3.64	d, 17.5 d, 17.5	2b 2a	2b, NMe 2a, NMe	1, NMe,1- pro 1, NMe,1- Pro	2b, NMe, 2-Pro 4-MeVal, 5- MeVal, NMe
	N-Me	34.9	2.87	S		2a, 2b	2, 1-Pro	2b, 3-MeVal
Me-Val	1	167.4	-	-	-	-	-	-
	2	71.3	2.70	d, 9.0	3, 4, 5	3, 4, 5	1, 3,4,NMe	4, 5
	3	26.9	2.62	d, 7.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5
	4	21.6	0.96	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
	5	19.2	0.72	d, 6.5	2, 3	2, 3, 4	2, 3, 4	3
	N-Me	39.2	2.89	S	-	2, 3	2, 1-Sar	2, 3, 5, 2a-Sar, 2b- Sar

β-ring	position	δc	δн	J (Hz)	COSY	TOCSY	HMBC	NOESY	
Thr	1	168.9	-	-	-	-	-	-	
	2	54.9	4.50	d, 9.0	3,4, -NH	3, 4	1, 3, 14	3, 4, 2-Val, Val-NH	
	3	74.6	5.23	m	2,4,- NH	2,4	4	2,4, Val-NH	
	4	17.6	1.20	d, 6.0	2, 3	2, 3, - NH	2, 3	2,3, Val-NH	
	NH	-	7.68	d, 6.0	2, 3, 4	2, 3, 4	1, 3, 14	2, 4	
L-Val	1	173.9	-	-	-	-	-	-	
	2	57.1	3.71	dd, 10.5, 6.5	3, 4, 5, - NH	3, 4, 5, -NH	1, 3, 5, 1- Thr,	3, 4, 5, 2-Oxo pro	
	3	31.8	2.20	m	2, 4, 5	2, 4, 5	2, 5	4, 5, 4-Thr	
	4	19.0	0.86	d, 7.0	2, 3	2, 3, -NH	2, 3, 5	2, 3, 5	
	5	18.8	1.14	d, 7.0	2, 3	2, 3, -NH	2, 3, 4	2, 3, 2-Val, Val-NH	
	NH		8.23	d, 6.0	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5, 2-Thr, 3- Thr	
Oxo- Pro	1	172.7	-						
	2	54.2	6.55	dd, 10.0, 2.0	3, 5	3, 5	3, 1-Val	3, 5, 2a-Sar, 2b-sar- NMe	
	3	41.8	2.32 2.13	d , 18.5 d, 13.0	2, 5 2, 5	2, 5 2, 5	1	2, 5 2, 5	
	4	208.0	-	-	-	-	-	-	
	5	53.7	3.83 3.90	d, 18.5 dd, 18.5, 12.0	2, 3 2, 3	2, 3 2, 3	1, 2 1, 2	2, 3 2, 3	
Sar	1	166.4	-	-	-	-	-	-	
	2	51.28	2a, 4.54 2b, 3.95	d, 19.5 d, 19.0	2b 2a	2b, NMe 2a, NMe	1, NMe, 1- Pro 1, NMe, 1- Pro	2b, NMe, 2-oxo-pro 4-MeVal , 5-MeVal, NMe	
	N-Me	34.7	2.88	S	-	2a, 2b	2, 1-Pro	2b, 2MeVal	
Me- Val	1	167.4	-	-	-	-	-	-	
	2	71.1	2.67	d, 8.5	3, 4, 5	3, 4, 5	1, 3, 4, 5, NMe	4, 5	
	3	26.8	2.60	d, 8.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5	
	4	21.5	0.93	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3	
	5	19.1	0.73	d, 6.0	2, 3	2, 3, 4	2, 3, 4	3	
	N-Me	39.0	2.91	s	-	2, 3	2, 1- Sar	2, 5, 2a-Sar, 2b-Sar	

Chromophore

Position	δc	δн	J (Hz)	COSY	TOCSY	НМВС	NOESY
1	101.8	-	-	-	-	-	-
2	147.3	-	-	-	-	-	-
3	179.0	-	-	-	-	-	-
4	113.4	-	-	-	-	-	-
<b>4</b> a	144.9						
5	-	-	-	-	-	-	-
5a	140.3						
6	127.6	-	-	-	-	-	-
7	130.2	7.34	d, 8.0	8, 11	8, 11	5a, 9, 11-Me	11
8	126.0	7.56	d, 7.5	7, 11	7, 11	9a, 5a, 13	11
9	132.1	-	-	-	-	-	-
9a	128.4	-					
10	-	-	-	-	-	-	-
11	14.9	2.52	S	7, 8	7, 8	5a, 6, 7	7, 8
12	7.6	2.18	S	-	-	3, 4, 4a	-
13	166.0	-	-	-	-	-	-
14	165.8	-	-	-	-	-	-





319 Fig. 4 a-m. Comparative analysis of MALDI-TOF-MS for molecular ion peak of 320 Transitmycin (R1), R2, R3. a R1 (Simulated). b R2 (Simulated). c R3 (Simulated). d R1 321 (Measured, positive mode. e R2 (Measured, Positive mode). f R3 (Measured, Positive 322 mode). g R1 (Measured, Negative mode). h R2 (Measured, Negative mode). i R3 323 (Measured, Negative mode), MALDI-TOF-MS spectra of crude extract of Streptomyces sp. 324 R2. j positive mode. k negative mode l Comparative analysis for HR-ESI-MS and MALDI-TOF-MS of Transitmycin (R1), R2 and R3 on various batches. m Characteristic retention 325 326 factor (R<sub>f</sub>) value and corresponding HR-ESI-MS data of purified compounds (Transitmycin 327 (R1), R2 and R3).

328

329



330 Fig. 5. a Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS, 331 **b** MALDI-TOF-MS spectrum of Transitmycin (R1). **c** Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS, 211- β-Ring-Val-Oxo-Pro, 233- α -Ring-332 333 Val-Pro, 294-β-Ring-Oxo-Pro-Sar-NMeVal, 295-Chromophore, 297- β-Ring-Thr-Val-Oxo-Pro, 357-α-Ring-Val-Pro-Sar-MeVal, 371-β-Ring-Val-Oxo-Pro-Sar-MeVal, 412-β-Ring-334 335 Val-Oxo-Pro-Sar-NMeVal, 412-α-Ring-Val-Pro-Sar-NMeVal+859 (Y ion), 495-β-Ring-336 Thr-Val-Oxo-Pro-Sar-NMeVal, 496- $\alpha$ -Ring-Thr-Val-Pro-Sar-NMeVal, 464  $\alpha$  - Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 746-Y-113 (MeVal), 747- a-Ring-Val-Pro-Sar-NMeVal+Y-337 338 MeVal+545.6,  $495=\beta$ -Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 495-371=124-23=101 MeVal

339 (β-Ring-Thr-Val-Oxo-Pro-Sar), 371(β-Ring-Thr-Val-Oxo-Pro-Sar), 294 (β-Ring-Thr-Val-

340 Oxo-Pro).

341

The MALDI-TOF-MS spectrum of crude extract of Streptomyces sp. R2 (Fig. 4j-k) and 342 343 measured, calculated mass of purified compounds Transitmycin (R1), R2, R3 were given in 344 (Fig. 4a-i, Supplementary Figure S70-115). The molecular formula was established as 345 C<sub>62</sub>H<sub>84</sub>N<sub>12</sub>NaO<sub>17</sub> based on Positive HRESI-MS, which showed protonated pseudo molecular 346 ion peak  $[M+H]^+$  at m/z 1270.7069 (Fig. 4a-m). It also showed intense peaks, due to Na and K adducts, at m/z 1291.8307 [M+Na]<sup>+</sup> and 1307.8124. [M+K]<sup>+</sup> respectively (Calcd. for 347 C<sub>62</sub>H<sub>84</sub>N<sub>12</sub>NaO<sub>17</sub>: 1291.5975: Found: 1291.8307). Fig. 4a-i Similarly, the MALDI TOF MS 348 349 spectrum of transitmycin showed intense peak in positive mode at m/z 1293.61316  $[M+Na+2H]^{+3}$  and at m/z 1309.93062  $[M+K]^+$  and in negative mode at m/z 1269.33344 350 351 [M-H]- (Fig. 4a-m, Fig. 4-5, Supplementary Information Fig. S115a-b). The compound R2 352 was isolated as orange red powder and its molecular formula was established as 353 C<sub>62</sub>H<sub>86</sub>N<sub>12</sub>O<sub>16</sub> [M+Na]<sup>+</sup> by positive HRESIMS. The MALDI TOF molecular ion of R2 354 showed peak at m/z 1278.95175 [M+Na+H]<sup>+</sup> and negative ion mode at m/z 1255.38052 [M-355  $H^{-}$  For a molecular formula of  $C_{62}H_{87}N_{12}O_{16}N_{6}$  its molecular weight is calculated as 356 1278.6261 [M+Na+H]<sup>+</sup> which matches with 1278.95175, that is similar to that of 357 actinomycin D (Fig. 3e). The compound R3 was obtained as an oranges red powder and the 358 molecular formula of R3 was determined to be  $C_{62}H_{87}N_{12}O_{17}$  from HR-ESIMS peak at m/z359 1271.7159z  $[M+H]^+$  and when calculated for the molecular formula ,  $C_{62}H_{87}N_{12}O_{17}$ 360 1271.6312, found to be 1271.7159 and 1277.6149 [M-OH-Na]<sup>+</sup>. The molecular formula of 361 R3 was established as C<sub>62</sub>H<sub>87</sub>N<sub>12</sub>O<sub>17</sub> by positive MALDI-TOF 1294.5888 [M+H+Na]<sup>+</sup> and negative mode 1268.4852 [M-H]<sup>-</sup> (Fig. 4f) which is identical to that of actinomycin 0ß 362 363 (Supplementary Information Fig. S70-115, S-Table S7a-b) [52-57].

The differences between compounds R1, R2, R3 were becaue of the variation in proline at 4<sup>th</sup> position. Transitmycin (R1) has keto group in the 4<sup>th</sup> position, R2 does not have keto group and compound R3 has hydroxyl group in the 4<sup>th</sup> position (Fig. 3a-c).

- 367
- 368
- 369

#### **370** HPLC Analysis of L-FDAA Derivatives of Transitmycin (R1)

371

372 HPLC experiment was used to determine the absolute configuration of isolated compounds. The absolute configurations of the amino acids were assumed to be identical to that of 373 actinomycin X<sub>2</sub>, as indicated by the negative optical rotation values and the strong cotton 374 effect at about 210 nm in the CD spectra. The assignment of the amino acids was carried out 375 primarily by the analysis of the <sup>1</sup>H-<sup>13</sup>C HSQC and <sup>1</sup>H-<sup>1</sup>H-COSYcorrelations, MALDI-TOF-376 MS (Fig. 4 a-m, S-Table S6), QTRAP LC-MS/MS (Supplementary Information Fig. S14-377 114, S115a-b, S-Table S7a-b), and completed with the help of HMBC spectrum (Fig. 3a-c). 378 379 Additionally, a small amount of compound Transitmycin and R3 were hydrolyzed and the 380 free amino acid were analyzed by HPLC, HR-LCMS, HR-ESIMS after chiral derivatization 381 with Marfey's reagent. Altered proline and sarcocine were not available as reference. 382 Although neither the altered proline and threonine moieties nor N-methylated alanine were 383 available as references, they can be assumed to possess L-configurations due to the fact that 384 the exchange of a single amino acid with its enantiomer leads to significant conformational changes of the respective peptidolactone ring, resulting in reduced biological activities as 385 386 well as chemical shift deviations that have not been observed. The absolute configuration of 387 the threonine, valine, methyl valine, proline in Transitmycin (R1) was clarified by Marfey's 388 method applied for the acid hydrolysate of Transitmycin (R1) in comparison with standard 389 amino acid analysis [60-64]. Retention times of the standard N<sup> $\alpha$ </sup>-(5-fluro-2,4-di-nitrophenyl)-390 L-alanamide (FDAA) derivatives were as follows: D-threonine, 15.682 min; L-threonine, 391 13.987 min; D-proline, 17.035 min; L-proline, 16.519 min; D-valine, 21.244 min; L-valine, 19.248 min; D-N-methyl valine, 22.089 min; L-Methyl valine 20.814 min. The 392 393 chromatogram of the FDAA derivatives of acid hydrolysate Transitmycin (R1) showed 394 peaks corresponding to L-Threonine (14.021 min), L-proline (16.520 min), L-valine 395 (19.252), L-N-methyl valine (21.263 min) were obtained in the hydrolysate. The above same 396 mentioned procedure for compound R3 was also done and similar results was obtained. 397 (Supplementary Information Fig. S116-125, Table S-8a-b) [60-64]. Comparison, with 398 authentic standards, revealed the presence of L-MeVal, L-Thr and D-Val as expected, 399 however the D-Valine is in L-configuration as well as one of the proline is in D-proline instead of L-configuration. (Fig. 6a-c). 400

#### HPLC data analysis for L-FDAA derivatives to hydrolysates of Transitmycin (R1) a) and standard amino acids

Amino acids	HPLC retent derivatives	tion time of Marfey's for standard amino acids	HPLC retention time of Marfcy's derivatives for acid hydrolysate of Transitmycin	Assignment	
	D	L	Rl		
Threonine	15.682	13.987	14.021	L	
Proline	17.035	16.519	17.055 & 16.520	D & L	
Valine	21.244	19.248	19.252	L	
N-methyl valine	22.089	20.814	21.263	L	



b)

HR-LCMS data analysis for L-FDAA derivatives to hydrolysates of Transitmycin c) (R1) and standard amino acids

Amino acids	LCMS reten Marfey's de standard a	ition times of rivatives for mino acids	HPLC retention time Marfey's derivatives for acid hydrolysate of	[M+H] <sup>+</sup> m/z	[M-H]- m/z	Assignment	
	D	L	Transitmycin R1				
Threonine	9.90	13.50	13.73	372.13	370.13	L	
Proline	15.16	14.31	14.23 &15.36	366.13	363.07	D&L	
Valine	19.65	17.65	18.02	370.13	368.07	L	
N-methyl valine	20.33	19.25	19.96	384.20	382.20	L	

401

402 Fig. 6. a HPLC data analysis for L-FDAA derivatives to hydrolysates of Transitmycin R1
403 and standard amino acids. b Graphical representation for RP-HPLC chromatogram of L404 FDAA (Marfey's) derivatives of hydrosylated Transitmycin (R1). c HR-LCMS data analysis
405 for L-FDAA derivatives to hydrolysates of Transitmycin R1 and standard amino acids.
406

# 407 LC-MS Analysis of L-FDAA Derivatives of Transitmycin (R1)

408 The retention times of the D- and L-FDAA derivatives of standard amino acid, 409 respectively, were as follows: Pro: 14.35, 14.97, min, m/z 366.13 [M +H]<sup>+</sup>, m/z 363.07 [M-410  $H_{+}^{+}$ ; Val: 19.63, 17.52 min, m/z 370.13  $[M+H]^{+}$ , 368.13  $[M-H]^{-}$ ; Thr: 9.90, 13.50 min, *m*/*z*372.07 [M+H]<sup>+</sup>, 370.13 [M – H]<sup>-</sup>; NMeVal: 20.33, 19.23 min, *m*/*z* 384.20[M+H]<sup>+</sup>382.20 411 412  $[M - H]^{-}$ . The L-FDAA was used to derivatize the acid hydrolysates of Transitmycin (R1), 413 R3 and eight standard amino acids (D-Val, L-Val, D-Thr, L-Thr, D-N-MeVal, L-N-MeVal, 414 D-Pro and L-Pro). The reaction with L-FDAA was performed with the same procedure as above. [63-64]. The retention times of the L-FDAA derivatives were as follows: D-Pro:15.16 415 416 min, L-Pro:14.31 min, m/z 366.13 [M+H]<sup>+</sup> 363.07 [M-H]<sup>-</sup>;D-Val: 19.65 min, L-Val 17.65 min m/z 370.13 [M+H]<sup>+</sup>368.07[M-H]<sup>-</sup>; D-Thr: 9.90 min, L-Thr, 13.50 min, m/z417 372.13[M+H]<sup>+</sup>370.13 [M-H]<sup>-</sup>; D-N-MeVal 20.33 min, L-N-MeVal 19.25 min, m/z 418 419 384.20[M+H]<sup>+</sup>,382.20 [M+H]<sup>-</sup>. The retention time of L-FLDA derivatives of acid 420 hydrolysates Transitmycin (R1) were as follows: L-threonine (13.73 min), L-Proline (14.23 421 min), D-Proline or keto-proline (15.36 min), L-valine (18.02 min), N-Methyl valine (19.96 422 min) as illustrated in Fig. 6 a-b. The retention time of L-FLDA derivatives of acid

hydrolysates (R3) (Supplementary Information Fig. S-128-161, S-Table S9 a and b) were as
follows: to L-threonine (12.45 min) or D-threonine (9.36 min), L-Proline (14.25 min), DProline or keto-proline (15.21 min), L-valine (17.49 min), N-Methyl valine (19.93).
Comparison with authentic standards revealed the presence of L-MeVal, L-Thr, L-Proline,
L-Valine and one of the Proline as in D-configuration (Fig. 6c). Hence, we named the
unusual newly found compound as Transitmycin (Fig. 3d, Table 1& 2), a member of the Xtype [35-64].

Transitmycin (R1)	Properties
TLC	Single yellow spot with R <sub>f</sub> value 0.8 (EtOAc:MeOH (9.5:0.5))
Color and consistency	Orange color amorphous powder
Yield	200 mg, 20%
Melting point (mp)	240-242°C
$[\alpha]_{D}^{25}$	-106 ° (c = 0.2, MeOH)
Solubility	Soluble in chloroform, dichloromethane, ethyl acetate, methanol, ethanol, acetonitrile, DMSO and water; Insoluble in Hexane
UV	(MeOH) $\lambda_{max}$ (log $\epsilon$ ) 214 (3.07), 240 (2.30), 425 (1.44), 442 (1.51) nm
CD	[MeOH, [nm], (mdeg)]: $\lambda_{max}(\Delta \epsilon)$ 195 (+11.1), 210 (-21.0), 242 (+4.7)
IR (KBr), <i>v</i> <sub>max</sub>	3435, 2958, 2924, 2853, 1745, 1642, 1524, 1465, 1379, 1194, 1099, 1059 cm <sup>-1</sup>
<sup>1</sup> H NMR (500MHz)	Table 2
<sup>13</sup> C NMR (125MHz,	179.0, 174.0, 173.5, 173.17, 169.0, 168.8, 167.5, 167.5, 166.5,
CDCl <sub>3</sub> ):	166.3,166.1, 165.9, 144.34, 145.93, 145.04, 140.5, 132.19, 130.3, 129.2,
	127.8, 126.1, 113.6, 101.8, 76.7, 74.76, 74.67, 71.4, 71.2, 58.5, 57.2, 56.4,
	54.9, 54.7, 54.3, 51.3, 29.6, 29.6, 29.3, 22.6, 21.7, 21.6, 19.2, 19.2, 19.09, 19.06, 18.8, 17.14, 14.11,7.77.
HRESI-MS	m/z (pos.ions) 656.9243 [M+2H] <sup>+2</sup> , 1270.7069 [M+H] <sup>+</sup> , 1291.8449 [M
	$+ Na]^{+1307.9286} [M + K]^{+}$
	$C_{62}H_{84}N_{12}O_{17}Na \ [M + Na]^+ \ calc. \ 1291.5975, found. \ 1291.8449$
MALDI-TOF-MS	m/z (pos.ions) 1293.61316 [M + Na+2H] <sup>+</sup> , 1309.93062 [M+K] <sup>+</sup>
	m/z (neg.ions) 1269.33344 [M-H] <sup>-</sup>
	$C_{62}H_{84}N_{12}O_{17}Na \ [M+Na+2H]^+ \ calc. \ 1293.61950, \ found. \ 1291.61316$
EI-MS: (70 ev)	<i>m</i> / <i>z</i> (pos.ions)1348.1437, 1291.4173 [M+Na] <sup>+</sup> , 1224.7363, 1191.8994,
	1023.6241, 886.0243, 743.2058, 614.8185, 347.6111, 202.5464, 138.5079
LCESI-MS	m/z (pos.ions) 1291.5995 [M + Na] <sup>+</sup> C <sub>62</sub> H <sub>84</sub> N <sub>12</sub> O <sub>17</sub> Na [M+Na] <sup>+</sup> calc. 1291.5975, found. 1291.5995
CHN	Anal. calcd for C <sub>62</sub> H <sub>84</sub> N <sub>12</sub> O <sub>17</sub> : C, 58.66; H, 6.67; N, 13.24.
	Found: C, 59.71; H, 7.28; N, 10.19.

**Table 2.** Physico-chemical properties of Transitmycin

431

#### **432** Determination of anti TB and anti-HIV activity

#### 433 Activity against planktonic cultures of M. tuberculosis

434 Despite the introduction of new anti TB drugs, emergence of antibiotic resistance among M. 435 tuberculosis strains remains a major challenge in tuberculosis therapy. According to WHO 436 Global Tuberculosis report - 2022, there is a 3.1% increase in incidence of multi drug 437 resistant and rifampicin resistant TB cases from 2020 to 2021[65]. Thus, there is a burning 438 need for more new antitubercular drugs to tackle drug resistant tuberculosis [66]. Since 1940s, secondary metabolites and their associated derivatives have played a key role in anti-439 440 TB drugs development. This is best exemplified by an extremely active aminoglycoside, 441 namely streptomycin, the first clinical drug that was made available against TB [67]. In a 442 previous study, Streptocytosines A, Bamitecin and Amitecin isolated from sea water 443 Streptomyces in Japan showed activity against M. smegmatis at 32, 16 and 8 µg/ml 444 concentrations, respectively [68]. In another study, actinomycin X2 and actinomycin D 445 isolated from marine Streptomyces sp. MS449 in China showed activity against M. 446 tuberculosis H37Rv at 1.92mg/ml and 1.77 mg/ml, respectively [69]. In the present study 447 Transitmycin, a novel molecule isolated from a marine *Streptomyces* sp. R2 picked up from 448 coral reef ecosystem showed activity notably against drug sensitive, multi drug resistant 449 (MDR) and mono resistant strains of *M. tuberculosis* at concentrations of 5 and 10  $\mu$ g/ml 450 (Fig. 7). Based on the preliminary experiment on laboratory strain, M. tuberculosis H37Rv, 451 minimum inhibitory concentration for transitmycin was determined on clinical isolates 452 which included 49 drug sensitive strains and 48 drug resistant strains. The drug resistant 453 profile of the clinical isolates are given in (supplementary S-table 12). Out of 97 clinical 454 isolates, MIC at 5 µg/ml was seen in 89 isolates and MIC at 10 µg/ml was seen in 8 isolates for transitmycin based on LRP assay. 455



Fig. 7. MIC of Transitmycin in micrograms per millilitre for *Mycobacterium tuberculosis*isolates susceptible to anti-TB drugs (n=49) and drug resistant to one or more anti-TB drugs
(n=48) as determined by LRP assay. Sensitive strains are represented in blue colour and
resistant strains are represented in brown colour.

#### 461 Activity against M. tuberculosis biofilm

462 Bacteria can persist for extended periods of time inside the biofilm due to their ability to 463 resist the immune system, display increased virulence and become phenotypically more resistant to antibiotics. Moreover, antibiotic concentrations required to control bacteria 464 465 within a biofilm are estimated to be 100-1,000 fold greater than that is needed to treat planktonic forms. As planktonically-grown *M. tuberculosis* are unlikely to be entirely 466 467 representing the bacterial load during human infection, we set out to determine how 468 effective transitmycin can be against *M. tuberculosis* growing as a biofilm, a bacterial 469 phenotype known to be more resistant to antibiotic treatment [70]. In the present study, M. 470 tuberculosis culture showed biofilm formation in the control wells alone which could be 471 observed by the naked eye. The wells with cells and transitmycin failed to produce biofilm. CFU determined prior to the addition of transitmycin was 1.9 x 10<sup>6</sup> to 2.3 x 10<sup>6</sup>/ml. After 4 472 days of exposure with the compound, the CFU dropped to  $9 \times 10^4$  to  $10 \times 10^4$  ml. Addition of 473 474 transitmycin completely killed all the cells at the end of 5 weeks (Table 3). 475

476

456

477

Culture	Zero days 10 <sup>5</sup> x CFU/ml		After 4 days 10 <sup>5</sup> x CFU/ml		Biofilm formation after 5 weeks	
<i>M. tuberculosis</i> alone	1.1	1.8	6.6	3.6	Present	
M. tuberculosis+ Transitmycin (10 μg/ml)	19.0	23.0	0. 9	1.0	0.0	

#### 478 Table – 3. Activity of transitmycin on biofilm formation

479

#### 480 Anti-HIV activity

481 The symbiotic association of TB and HIV poses a challenge to human survival in which HIV 482 complicates the treatment and diagnosis of TB. Besides, HIV-TB patients encounter other 483 unique problems such as cumulative toxicity, immune reconstitution inflammatory syndrome 484 (IRIS), drug-drug interactions, lower plasma drug levels, and the emergence of drug 485 resistance during treatment [71]. The currently available therapy for treating patients co-486 infected with HIV and TB requires a very high pill load. Therefore, a class of drugs that can 487 be used to treat TB and HIV would be a real breakthrough in TB and AIDS Research. 488 Hence, the present study also evaluated the anti-HIV activity of transitmycin. A dose-489 dependent reduction was observed in HIV-1 p24 levels in viral culture indicating that 490 transitmycin possessed significant anti-HIV activity. Transitmycin demonstrated good anti-491 viral activity against the different subtypes of HIV-1 as well as clinical isolates obtained 492 directly from HIV-infected persons. In addition, transitmycin was also active against HIV-1 493 viruses resistant to nevirapine and AZT (Fig. 8a). The estimated IC<sub>50</sub> value ranged between 494 0.19 and  $0.65\mu$ g/ml for the viruses tested. There was a >50% inhibition at a concentration of 495 0.1µg/ml and 80-95% inhibition at a concentration of1µg/ml in the clinical isolates (Fig. 10b). The compound demonstrated a remarkable inhibitory effect on primary isolates 496 497 belonging to various subtypes as well as to clinical isolates obtained from HIV-infected 498 individuals. IC<sub>50</sub> values calculated for the various strains tested indicate that transitmycin is 499 a potent inhibitor of HIV-1 under *in vitro* experimental conditions. Importantly, transitmycin 500 also inhibited drug resistant forms of the virus, in a dose-dependent manner. These findings 501 suggest that transitmycin holds promise as the first potent compound that can be used to

treat TB and HIV infections when they occur singly, as well as in combination as HIV/TBco-infection. (Supplementary S-table 13).



# 504

505

Fig. 8 a Activity of Transitmycin against different HIV-1 clades. Various concentrations of 506 507 Transitmycin were tested using 100 TCID<sub>50</sub> of virus belonging to 6 different HIV-1 clades as 508 well as two drug-resistant strains. Each concentration was tested in triplicate on all the 509 indicated viruses and mean  $\pm$  SEM values are shown in the graph. Log<sub>10</sub> -2 in the figure 510 equals 0.01  $\mu$ g/ml, Log<sub>10</sub> -1 equals 0.1  $\mu$ g/ml, Log<sub>10</sub> 0 equals 1  $\mu$ g/ml and Log<sub>10</sub> 1 equals 10 511 µg/ml. **b** Activity of Transitmycin on clinical isolates obtained from HIV-1 infected 512 individuals. Three concentrations of Transitmycin and two concentrations of AZT were 513 tested against 20 clinical isolates and mean + SD values are shown on the graph. This 514 experiment was performed on two different occasions.

515

#### 516 R1, R2 and R3 intercalates with the genomic DNA of Mycobacterium tuberculosis

517 Actinomycin D is the structurally similar compound for R1, R2 and R3. Actinomycin D and 518 its derivatives are reported to intercalate with the DNA and exhibits fluorescence. So, we 519 tested R1, R2 and R3 for its properties of DNA intercalation and fluorescence. Ethidium 520 bromide 0.5 µg/ml is used as a positive control. The relative fluorescence unit (RFU) of R1, 521 R2 and R3 with the DNA is compared with the RFU of R1, R2 and R3 without DNA. The 522 average RFU of Ethidium bromide was 8561429. From the experiment, it was observed that 523 all the three compounds, R1, R2 and R3 have DNA intercalating property and exhibits 524 fluorescence (Fig. 9).

- 525
- 526



Fig. 9 a) R1, b) R2 and c) R3 binds with the DNA and emit fluorescence in a dose dependent manner. The concentrations of R1, R2 and R3 tested were 0.5  $\mu$ g/ml, 1  $\mu$ g/ml, 2  $\mu$ g/ml and 5  $\mu$ g/ml. As the concentration increases, the Relative fluorescence unit (RFU) also increases.

# 539 Docking and molecular dynamics studies

The concept behind docking was to assess the potential interaction between the transitmycin Fig. 10a or its derivative molecules and various DNA/Protein targets of interest. Through docking studies, we aimed to validate the anticipated interactions, even though comprehensive molecular dynamics studies were restricted, particularly for the entire transitmycin or its derivatives. Nevertheless, the chromophore part Fig. 10b molecular dynamics dynamics displayed enhanced stability, indicating promising outcomes in our research

547 We performed docking and molecular docking experiments with a specific target and three 548 ligands: R1, R2, and R3. Our analysis showed that 1MNV displayed favorable interactions 549 with R2, whereas 3PKE exhibited superior binding with R3 Fig. 10c. The docking score data 550 is presented in Table 4.

- 551 Docking Score: docking scores were determined using the knowledge-based iterative 552 scoring functions ITScorePP or ITScorePR. A more negative docking score implies a higher 553 likelihood of a binding model. However, it's important to note that the score doesn't 554 represent the true binding affinity, as it hasn't been calibrated against experimental data.
- 555 Confidence Score: To gauge the likelihood of binding between two molecules, we 556 introduced a confidence score based on docking scores. The formula for the confidence 557 score is:
- 558 Confidence\_score=1.01.0+e0.02×(Docking\_Score+150)Confidence\_score=1.0+e0.02×(Doc 559 king\_Score+150)1.0

- 560 In this context, when the confidence score surpasses 0.7, it suggests a high probability of
- 561 binding. Scores between 0.5 and 0.7 indicate a possible binding, whereas scores below 0.5
- 562 imply an unlikely binding.
- Ligand RMSD: Ligand RMSD values were computed by comparing ligands in the dockingmodels with the input or modelled structures.
- **Table 4**. The docking score data of specific target (1MNV, 3PKE, 1MO3, 3IU8) and three ligands: R1, R2, and R3

Name of the Molecule	Docking Score	Confidence Score	Ligand RMSD (A)
1MNV with R1	-489.71	0.9989	22.52
1MNV with R2	-518.80	0.9994	17.61
1MNV with R3	-532.55	0.9995	25.15
1MO3 with R1	-397.33	0.9929	83.36
1MO3 with R2	-424.84	0.9959	83.95
1MO3 with R3	-420.99	0.9956	83.36
3PKE with R1	-391.53	0.9921	52.95
3PKE with R2	-493.89	0.9990	50.96
3PKE with R3	-503.74	0.9992	57.70
3IU8 with R1	-337.77	0.9771	37.59
3IU8 with R2	-418.79	0.9954	47.58
3IU8 with R3	-437.87	0.9969	50.75

567

568

569

We conducted Molecular Dynamics (MD) simulations for the complex 1MNV with R2 and R3. Unfortunately, MD simulations for R2 and R3 couldn't be performed due to the large size of their peptide side chains, preventing accommodation into the minor groove of DNA (1MNV). However, we successfully carried out simulations with the chromophores of R2 and R3. The RMSD of the residues remained within acceptable limits during these simulations.

576 Additionally, MD simulations were conducted for the complex 3PKE with R3. Similar 577 challenges were encountered with the peptide side chains, leading to simulations being 578 performed with the chromophore, as illustrated in Figure 10b. The RMSD values plotted 579 against residues are presented in Figure 10e.

- 580 The results of the MD simulations indicate the stability of the protein backbone throughout 581 the simulation period. However, it is noteworthy that the simulations faced computational 582 challenges, primarily due to the size of the peptide side chains. Despite these difficulties, the 583 obtained data provides valuable insights into the behavior of the complexes during the
- 584 simulations.

585



586

587

588 Fig 10. a) Transitmycin structure b) Chromophore part of transitmycin or its derivatives,
589 c) 1 MNV R2 Docking Pose d) 3PKE with R3 Docking pose e) RMSD values of Residues
590 during the simulation Plot (3PKE with R3).

591

#### 592 Methods

#### 593 Characterization and taxonomy of *Streptomyces* sp. R2

594 Micromorphology of potential *Streptomyces* sp. R2 was studied by adopting Transplantation 595 Embedding Technique [72]. Briefly, a rectangular trough was dug out of an ISP2 agar plate 596 using sterile knife. Then the spores of *Streptomyces* strain were inoculated on the edges of 597 the trough under aseptic condition. A sterile cover-slip was placed over the agar, touching 598 the inoculated area on the ISP2 agar plate. The plate was incubated at 28°C for 7-14 days. 599 The cover-slip was aseptically removed using sterile forceps and placed over clean 600 microscopic slide fixing the same using cellophane tape. Micromorphology of *Streptomyces* 601 sp. R2 was observed under bright field microscope (Olympus) under 10x and 40x 602 magnifications. Spore structure and spore surface morphology were recorded using a 603 scanning electron microscope (JEOL model JSM5600LV). Media and procedures used for 604 determination of cultural characteristics and carbon and nitrogen source utilization were 605 those described originally by Shirling and Gottileb [24]. Effect of pH, temperature, NaCl concentration and anaerobic condition were studied using modified ISP2 medium. Antibiotic 606 607 susceptibility pattern was determined by disc diffusion method using standard antibiotic 608 discs (Hi media) following the standard protocol [73]. Biomass for cell wall analysis was 609 prepared by growing Streptomyces sp. R2 in shake flasks (120 rpm) containing ISP2 broth at 28 <sup>o</sup>C for 5 days. Amino acid and sugar content analyses of whole cell hydrolysates were 610 611 performed according to the original procedure described by Staneck and Roberts [74].

612

#### 613 Molecular characterization and phylogenetic analysis

614 Streptomyces sp. R2 was grown in 50 ml of ISP2 broth at 28°C for 48 h. The genomic DNA 615 was extracted using Chromous genomic DNA isolation kit. Polymerase chain reaction 616 (PCR) was performed for the amplification of 16S rRNA gene using the primers 5' -617 AGAGTRTGATCMTYGCTWAC - 3' and 5' - CGYTAMCTTWTTACGRCT - 3' on a ABI12720 thermal cycler (Applied Biosystems). The conditions used for thermal cycling 618 619 were as follows: initial denaturation at 94<sup>o</sup>C for 4 min, followed by 35 cycles consisting of denaturation at 94°C for 30 sec, primer annealing at 55°C for 30 sec and primer extension at 620 72°C for 2 min, followed by a final extension at 72°C for 5 min. The amplified 16s rRNA 621 622 gene fragment (~ 1.4 kb) was separated by agarose gel electrophoresis and the purified 623 fragment was used for sequencing in an ABI3130 genetic analyser. The nearly complete 16s 624 rRNA gene sequence of strain R2 (1400 nt) was subjected to BLAST comparison against the 625 16s rRNA sequences given in GenBank/DDBJ/EMBL databases.

626 Phylogenetic analysis was performed using CLUSTAL-W and MEGA version 3.1.

- 627 Evolutionary distances (Kimura's two parameter model) [75] and clustering were calculated
- 628 employing the neighbour-joining method. The topology of phylogenetic tree was evaluated
- 629 by the bootstrap re-sampling method with 1000 replicates.
- 630

# 631 **Production of Transitmycin**

- 632 Hundred microliters of Streptomyces sp. R2 spore suspension was transferred into 10 YEME 633 agar plates and spread using sterile L- rods. The plates were incubated at 28°C for 10 days. 634 After every 24 hours of fermentation, the mycelial growth was scrapped out and the crude 635 pigment secreted into the agar medium was extracted using equal volume (1:1) of different 636 organic solvents such as n-hexane, dichloromethane, chloroform, ethyl acetate and methanol 637 for 24 hours. The solvent portion was collected and dried at 40°C using Concentrator plus 638 (Eppendorf) [76]. Anti TB activity of crude extracts were tested against M. tuberculosis 639 H37Rv at 100µg concentration adopting LRP assay [77].
- 640 *Streptomyces* sp. R2 was cultured for 10 days at 28<sup>o</sup>C on YEME agar plates (2000 ml of 641 medium in 100 petriplates of 90 mm diameter) to produce the culture extract in bulk. After 642 the incubation period, the cell material was aseptically removed and discarded after 643 autoclaving. The yellow pigmented antibiotic containing agar medium was cut in to pieces 644 and extracted twice with equal volume (1:1 ratio) of ethyl acetate for 24 hours.
- 645

#### 646 **Purification of transitmycin**

647 Transitmycin was purified by preparative thin layer chromatography (TLC) using Merck 648 silica gel 60 (GF254) pre coated aluminium (6x8 cm size) plates. The extract was separated 649 using different solvents in different proportions. After running, the 200 sheets were kept at 650 room temperature for complete drying of the plate. Spots on TLC were detected through 651 naked eye as well as under UV light (254 and 365 nm). After drying, three major yellow 652 colour spots (R1, R2 and R3) were scrapped, mixed with ethyl acetate and filtered using a 653 funnel fitted with Whatman filter paper. Ethyl acetate was evaporated to dryness under 654 vacuum to obtain the compounds as dry amorphous powder. (Supplementary Fig. S2).

All three compounds were tested against *M. tuberculosis* H37Rv at 100  $\mu$ g concentration by LRP assay. All three compounds from the ethyl acetate extract was purified using column chromatography packed with neutral alumina using a gradient of 1% methanol/chloroform mixture (CH<sub>3</sub>OH/ CHCl<sub>3</sub>) as the eluent. Fractions were collected and

659 concentrated under vacuum to obtain pure transitmycin. The product was visualized in a660 silica gel coated TLC sheet (Supplementary Fig. S2 and S3).

661 The compound R1 (named as transitmycin) that showed maximum activity was taken 662 for characterization and other studies testing its biological activity. Purity of transitmycin 663 (Fig. 2c). was analysed by HPLC using Shimadzu (Japan) RID-10A gradient high-664 performance liquid chromatographic instrument, equipped with two LC-20AD pumps 665 controlled by a CBM-10 inter-face module. Refractive index Detector RID 10A (Shimadzu) was used for the peak. Analysis was performed on a Luna 5u  $C_{18}$  (2) reversed-phase column, 666 667 100 (150X4.6mm). The analytical parameters were selected after screening a number of 668 solvent systems and gradient profiles. Separation was achieved using a two-pump gradient 669 program for pump A (0.1% Acetic acid in CH<sub>3</sub>CN) and pump B (0.1% Acetic acid in H<sub>2</sub>O) 670 in a linear gradient of acetonitrile and water from 0:100 to 65:35 in 65 minutes at a flow rate 671 of 2 ml/min. Detection was done at 254 nm, the absorption maxima close to that of majority 672 of the compounds. Injection size for sample was 20 µl. Column temperature was 30°C. 673 (Supplementary Fig. S4 and S5).

674

### 675 Characterization and structure elucidation

676 Colour and consistency of the purified antibiotic was visually observed. Solubility 677 was tested in water, methanol, acetone, ethyl acetate, diethyl ether, dichloromethane, 678 chloroform, and n-hexane by dissolving 1 mg of purified antibiotic. Optical rotations were measured with a Autopol IV Automatic polarimeter, and the  $[\alpha]_D$  values are given in deg 679 cm<sup>2</sup> g<sup>-1</sup>. Melting point was analysed using Mettler Toledo Model FP62 [78]. Ultraviolet 680 681 (UV) spectrum was determined using Shimadzu UV-1700 series. One milligram of sample 682 was dissolved in 10ml of methanol and the spectra were recorded at wavelength between 683 190 - 900 nm. The Infrared (IR) spectrum of the purified antibiotic was determined on 684 Perklin Elmer Spectrum One FT-IR. The spectrum was obtained using potassium bromide (KBr) pellet technique in the range of 450 to 4000 cm<sup>-1</sup> at a resolution of 1.0 cm<sup>-1</sup>. 685 686 Potassium bromide (AR grade) was dried under vacuum at 100°C and 100 mg of KBr with 687 1mg of purified antibiotic was used to prepare KBr pellet. The spectrum was plotted as intensity versus wave number [79]. <sup>1</sup>H and <sup>13</sup>C NMR spectra were recorded on a Bruker 688 Advance 500 NMR spectrometer in CDCl<sub>3</sub> with TMS as internal Standard and with 689 690 chemical shifts ( $\delta$ ) reported in ppm. Two-dimensional <sup>1</sup>H–<sup>1</sup>H COSY, DQF-COSY, NOESY, ROESY, <sup>1</sup>H-<sup>13</sup>C HSQC, HMBC, and spectra were recorded on a Bruker Advance 500 NMR 691 692 spectrometer. MALDI-TOF MS analyses were performed using an Applied Biosystems

693 ABI4700 TOF mass spectrometer in reflector mode with an accelerating voltage of 20 kV.

694 HRESIMS were measured on a Q-TOF micro mass spectrometer (Waters USA) in positive

- 695 ion mode with methanol as solvent. QTOF- MS was recorded on an Agilent 6520-QTOF
- 696 LCMS having an ESI source in positive mode.
- 697

# 698 HPLC Analysis of L-FDAA Derivatives of Transitmycin

699 Transitmycin (3.0 mg) was dissolved in 1 ml of 6NHCl and heated in a sealed glass 700 tube at 110°C for 24 h. After removing the solvents, the hydrolysate mixture (3 mg) and the 701 amino acid standards (0.5 mg) were separately dissolved in 0.1 mL of water and treated with 702 0.2 mL of 1% 1-fluoro-2,4-dinitrophenyl-5-L-alaninamide (FDAA) (Marfey's reagent) in 703 acetone (10 mg/mL in acetone) and 0.04 mL of 1.0 M sodium bicarbonate. The vials were 704 heated at 50°C for 90 min, and the contents after cooling at room temperature were 705 neutralized with 1N HCl. After degassing, an aliquot of the FDAA derivative was diluted in 706 CH<sub>3</sub>CN, Water (1:1) and analysed by reversed phase HPLC column Luna 5u C<sub>18</sub> (2) 100 707 (150X4.6mm) and a linear gradient of acetonitrile and water containing 0.05% 708 trifluoroacetic acid from 10:90 to 50:50 in 20 min and then isocratic. The flow rate was 709 adjusted to 1 mL/min and the absorbance detection was at 340 nm. The chromatogram was 710 compared with those of amino acid standards treated in the same conditions [60-61].

711

### 712 LC-MS Analysis of L-FDAA Derivatives of Transitmycin

The analysis of the L- and D-FDLA derivatives of Transitmycin was performed on a Waters Acquity UPLC coupled with a Thermo LCQ Deca XP MAX. QTOF- MS was recorded on an Agilent 6520-QTOF LCMS having a ESI source in Positive mode and employing a linear gradient of from 25% to 70% CH<sub>3</sub>CN in 0.01 M formic acid at 0.5 mL/min over 60 min [62-64].

718

Transitmycin (R1). R1 was obtained as an orange red solid;  $[α]_D^{25}$  -106 ° (c 0.2, MeOH); UV (MeOH) λ max (log ε) 214 (3.07), 240 (2.30), 425 (1.44), 442 (1.51) nm; CD [(MeOH),(mdeg)] λ<sub>max</sub>(Δε) 195 (+11.1), 210 (-21.0), 242 (+4.7) nm; IR (KBr), ν<sub>max</sub> 3435, 2958, 2924, 2853, 1745, 1642, 1524, 1465, 1379, 1194, 1099, 1059 cm<sup>-1</sup>; HRESI-MS (pos.ions): *m/z* 1270.7069 [M+2H]<sup>+</sup>,1291.8449 [M+Na]<sup>+</sup>, 1307.9286 [M+K]<sup>+</sup>657.3119 [M+2H]<sup>+2</sup>; MALDI-TOF-MS (pos.ions):*m/z* 1293.07095 [M+Na+2H]<sup>+</sup>, 1309.93062

- 725  $[M+K]^+$  MALDI-TOF-MS (neg.ions) 1269.33344  $[M-H]^-$  <sup>1</sup>HNMR, <sup>13</sup>NMR and 2DNMR 726 details (Supplementary Fig. S14-52, S-Table 5).
- 727

Compound (R2). R2 was obtained as a red solid;  $[α]_D^{25}$ : -24° (c 0.2, MeOH); UV(MeOH) λ max, (log ε) 205(1.25),240(0.63),425 (0.39), 442 (0.42) nm; CD [MeOH, (mdeg)] λ<sub>max</sub>, (Δε) 195 (+8.8), 210 (-22.0), 240 (+4.3) nm;IR (KBr),  $v_{max}$ 3436, 2961, 2924, 2853, 1744, 1650, 1565, 1415, 1204, 1140, 1045, 1019 cm<sup>-1</sup>; HRESI-MS (pos. ions) :1277.8245 [M + Na]<sup>+</sup>1293.8735 [M + K]<sup>+</sup>m/z 650.3413 [M+2H]<sup>+2</sup>; MALDI-TOF-MS *m/z* (pos.ions) 1278.95175 [M+Na+H]<sup>+</sup>; MALDI-TOF-MS (neg.ions) *m/z* 1255.38052 [M-H]<sup>-</sup>, <sup>1</sup>HNMR, <sup>13</sup>NMR and 2D NMR details (Supplementary Fig. S53-63).

735

**Compound (R3):** R3 was obtained as orange solid;  $[\alpha]_D^{25}$ :-27 ° (c 0.2, MeOH); UV 736 (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) nm; CD [MeOH, 737 738 (mdeg) ]  $\lambda_{max}$  ( $\Delta\epsilon$ ) 195 (+24.0), 210 (-21.5), 241 (+1.7) nm; IR (KBr),  $v_{max}$  3415, 2957, 2924, 1642, 1583, 1464, 1384, 1193, 1093, 1078 cm<sup>-1</sup>; HRESI-MS 739 2853. 1745. 740 (pos.ions):1271.7159 [M +H]<sup>+</sup> *m*/*z*1277.6149 [M-OH+Na]<sup>+</sup>; MALDI-TOF-MS (pos.ions) 741 m/z 1294.5888 [M + Na]<sup>+</sup> MALDI-TOF-MS (neg. ions) m/z 1268.48582 [M-H]<sup>-</sup>, <sup>1</sup>HNMR, <sup>13C</sup>NMR and 2D NMR details, (Supplementary Fig. S64-69). 742

743

#### 744 Determination of anti TB and anti-HIV activity

745 Anti-TB activity was determined by adopting Luciferase Reporter Phage (LRP) assay 746 against the standard laboratory strain, Mycobacterium tuberculosis H<sub>37</sub>Rv, and 97 clinical M. 747 tuberculosis isolates including drug sensitive and cultures exhibiting different drug resistant 748 patterns. Different concentrations  $(5 - 50 \mu g/ml)$  of purified antibiotic – transitmycin were 749 prepared using 10% dimethyl sulfoxide (DMSO). About 50µl of antibiotic solution was 750 added to 350 µl of glycerol 7H9 broth in cryo vials. Effect of DMSO was also tested by 751 adding 50 µl of 10% DMSO instead of the antibiotic. Mycobacterial cell suspension 752 equivalent of 2 McFarland units was prepared from log phase culture and 100 µl of the same 753 was added to all the vials before incubating at 37°C for 72 hours. After incubation, 50 µl of 754 high titre luciferase reporter phage phAE129 and 40 µl of 0.1M CaCl2 were added to test 755 and control vials. All the vials were incubated at 37°C for 4 hours. After incubation 100 µl 756 of suspension from each vial was transferred to a luminometer cuvette. 100 µL of D-757 luciferin was added and relative light unit (RLU) was measured in a luminometer [77].

Percentage of inhibition was calculated using the RLU of control and test and MIC wasdetermined. [81,82]

- 760
- 761

#### 762 Activity against *M. tuberculosis* biofilm

763 Cell suspensions of *M. tuberculosis* H37Rv were prepared using 7H9 broth. Biofilms of *M.* tuberculosis were developed on 6 well tissue culture plates by adding 2 ml of Sautons 764 765 medium (without Tween 80) and inoculating 20  $\mu$ L of saturated planktonic culture of M. 766 tuberculosis H<sub>37</sub>Rv. The plate was wrapped with parafilm and incubated without shaking at 767 37°C in humidified conditions for 7 to 14 days. The plate was observed regularly after 7 768 days for biofilm formation by *M. tuberculosis* which can be visibly seen. When the biofilm 769 was formed, 10 µg/ml of transitmycin was added to the transitmycin test wells leaving the 770 controls and considered as zero day. The viable counts of tubercle bacilli were determined from the wells on zero day, 4<sup>th</sup> day and after 5 weeks and expressed in cfu/ml [80]. 771

#### 772 Anti-HIV activity

**Viruses:** HIV-1 viruses belonging to subtypes A, B, C, D, E and A/C (Subtype A: 92RW020, Subtype B: JR-FL, Subtype C: 92BR025, Subtype D: 92UG001, Subtype E: 92TH021 and Subtype A/C: 92RW009), were obtained from the NIH AIDS Repository (Germantown, MD, USA). Clinical isolates of HIV-1 were produced in our laboratory by co-culture of HIV-infected peripheral blood mononuclear cells (PBMC) with activated donor PBMC.

779

# 780 Testing for anti-HIV activity

781 Anti-HIV activity of Transitmycin was determined using the HIV-1 gag p24 inhibition 782 assay. Initially, testing was performed on a lab-adapted HIV-1 subtype B isolate, HIV-1 783 IIIB. Donor PBMC were obtained from healthy volunteers after obtaining the approval of 784 the Institutional Ethics Committee of the National Institute for Research in Tuberculosis as 785 well as the informed consent of the participants. Donor PBMC were stimulated with PHA 786 (Phytohemeagglutinin) for 72 hours and incubated with 100 TCID<sub>50</sub> of the virus per 1 x  $10^6$ 787 cells for 4 h at 37°C. The cells were washed to remove the un-adsorbed virus and plated at a 788 concentration of 10,000 cells/well in a 96-well tissue culture plate. Varying concentrations 789 of Transitmycin (0.01µg/ml, 0.1µg/ml, 1.0µg/ml and 5.0µg/ml) were added to triplicate

- 790 wells. Control cultures were set up without the addition of the compound. AZT was used as
- the reference compound. Cultures were maintained for 7 days at  $37^{\circ}$ C in a CO<sub>2</sub> incubator.
- 792 On day 7, HIV-1 gag p24 antigen production was determined as an indirect measure of viral
- replication in the culture supernatants using the Alliance HIV-1 p24 ELISA kit (Perkin
- 794 Elmer, USA).
- 795 Testing of Transitmycin against different HIV-1 subtypes

796 Anti-viral activity of Transitmycin was also tested on primary HIV-1 isolates belonging to 797 different subtypes - Subtype A: 92RW020, Subtype B: JR-FL, Subtype C: 92BR025, 798 Subtype D: 92UG001, Subtype E: 92TH021 and Subtype A/C: 92RW009, as well as a 799 Nevirapine resistant and AZT resistant strain, using the method described above. The 800 activity of Transitmycin on different viruses was determined by measuring HIV-1 p24 801 antigen in 7-day culture supernatants. The IC<sub>50</sub>value (concentration of compound required to 802 inhibit 50% of virus replication) of Transitmysin for the different HIV- 1 subtypes was 803 calculated by fitting a dose response curve using a non-linear regression analysis to generate 804 a sigmoidal three parameter dose response curve (GraphPad Prism, version 6).

#### 805 Activity against clinical strains of HIV

Anti-viral activity of Transitmycin was further evaluated on 20 clinical isolates of HIV-1 obtained by co-culture of patient PBMC with PHA-stimulated donor PBMC in the laboratory. For this analysis, only three concentrations (0.01  $\mu$ g/ml, 0.1  $\mu$ g/ml and 1 $\mu$ g/ml) of transitmycin was used based on the results of the above experiment.

#### 810 DNA binding and Fluorescence assay

811 0.5  $\mu$ g/ml, 1  $\mu$ g/ml, 2  $\mu$ g/ml and 5  $\mu$ g/ml of R1, R2 and R3 were separately added to 100  $\mu$ l 812 of PBS in triplicates in 96 well plate. Mycobacterium tuberculosis genomic DNA was 813 extracted and 200 ng of DNA is added to each test wells. DNA was not added to the control 814 wells of R1, R2 and R3. For the positive control, 0.5 µg/ml of Ethidium bromide is taken in 815 PBS and 200 ng of DNA is added to it. After 15 mins, the plate is read in Multimode - plate 816 reader, Spinco Biotech, with excitation 546 nm and emission 595 nm. The relative 817 fluorescence unit is recorded. Average of RFU for each concentration of R1, R2 and R3 was 818 taken and plotted as graph.

- 819
- 820

#### 821 Conclusion:

822 Globally, the general public has latent or active tuberculosis, and this is expected to 823 increase in the future, causing the medical system a major challenge. The need of the hour is 824 to identify novel antibiotics to support the current regimens with reduced side effects, 825 duration and cost of treatment. Transitmycin is a novel antibiotic isolated from a novel 826 Streptomyces sp. MTCC from the coral reef soil from Rameshwaram waters in India. It has 827 the unique property of killing latent and active forms of TB bacilli irrespective of the 828 resistance they have towards major antiTB drugs and also sterilising the different resistant 829 and recombinant clades of standard and clinical HIV virus. When brought into the market 830 for human use, transitmycin can strategize treating TB and HIV simultaneously, which could 831 be a major breakthrough, none the less. Of course, preclinical trials and toxicity studies need 832 to be performed before it can be tested on human volunteers which will require sufficient 833 resources. Countries which are burdened with this dual ailment may have to take 834 considerable interest in this direction. Structural medications to the parent compound can 835 further improve its activity.

836

### 837 Acknowledgement

838

Professor Balasubramanian Kalpattu Kuppusami, INSA Senior Scientist, Department of
Chemistry, IIT Madras Chennai 600 036, India and Professor Krishna Kumari Gadepalli
Narasi, Department of Medicinal Chemistry, Sri Ramachandra University, Chennai 600 116,
India, acknowledged for discussion of structure elucidation of Transitmycin. Technical
assistance of Dr. S. Balaji and Dr. A. S. Shainaba of National Institute for Research in
Tuberculosis is acknowledged in fine tuning and uploading the manuscript.

# 845 Supplementary materials

The comprehensive characterization of the anticipated products have been subjected through UV/Vis, IR, CD, CHNS analyses, whilst, followed by <sup>1</sup>H-NMR <sup>13</sup>C-NMR, <sup>1</sup>H-<sup>1</sup>H COSY, <sup>1</sup>H-<sup>1</sup>H DQF-COSY, <sup>1</sup>H-<sup>13</sup>C HMBC, and <sup>1</sup>H-<sup>13</sup>C HSQC, <sup>1</sup>H-<sup>1</sup>H TOCSY, <sup>1</sup>H-<sup>1</sup>H NOESY, <sup>1</sup>H-<sup>1</sup>H NOESY 2D NMR spectra and MALDI-TOF-MS, HR-ESIMS, HR-LCMS, ESI-MS, QTRAP LC-MS/MS, RP-HPLC and LCMS analyses respectively. The following L-FDAA derivatives of R1, R2, R3 spectral information on all compounds of this article can be found in the online version.

853	
854	
855	Funding Received for this study
856	1) Potential Tuberculosis Drugs from Marine Actinomycetes, Funded by Department of
857	Science and Technology, New Delhi (November, 2007 to November, 2009).
858	2) Study to evaluate the baseline anti TB and anti-HIV properties of novel antibiotic
859	transitmycin (Tr) isolated from novel Streptomyces Sp. R2 funded by Indian Council of
860	medical Research (2009-2012).
861	3) Purity and in vitro efficacy studies on transitmycin funded by Indian Council of Medical
862	Research (2015-2016).
863	
864	Authors' individual contributions
865	Vanaja Kumar - Principal Investigator, planning, supervision, coordination and data
866	compilation, manuscript writing and editing.
867	Balagurunthan Ramasamy-Facilitating Growing of producer strain, coordination in crude
868	extract preparation as lab head.
869	Mukesh Doble - Purification of compound from crude extract, structure analysis and
870	chemical characterisation and report preparation as lab head.
871	Gandarvakottai Senthilkumar Arumugam – Isolation, purification, characterization,
872	complete structural elucidation and a key role in Innovation Of Transitmycin drug discovery
873	development and manuscript writing and editing.
874	Kannan Damodharan - Isolation, purification, characterization, structural elucidation of
875	Transitmycin compounds and final manuscript drafting.
876	Radhakrishnan Manikkam- Isolation and characterisation of producer strain, biological and
877	biochemical characterisation, testing biological activities, data compilation, manuscript
878	writing.
879	Hanna Luke Elizabeth - Testing crude extract and purified compound on HIV standard and
880	clinical clades. Preparation of write up.
881	Suresh Ganesan - Isolation, purification, characterization, structural elucidation of
882	Transitmycin compounds and final manuscript drafting
883	Azger Dusthackeer- Testing biological activities against latent bacilli and biofilms,
884	preparing the write up.
885	Precilla Lucia – Laboratory work for testing the compound on HIV clades.

- 886 Shainaba A Saadhali- Testing biological activities against latent bacilli and biofilms,
- 887 preparing the write up.
- 888 Shanthi John laboratory work with respect to growing the producer strain and preparation
  889 of crude extract.
- 890 Poongothai Eswaran laboratory work with respect to growing the producer strain and
- 891 preparation of crude extract.
- 892 Selvakumar Nagamiah– supervision of laboratory work on testing biological activities,
  893 editing manuscript.
- Soumya Swaminathan Facilitating coordinated activity for fund release, conduct of
  experiments against HIV clades as Head of the laboratory and the Institute.
- Jaleel UCA-Provided the overall conceptualization of theoretical study, and offered
  guidance throughout the research process and reviewed and edited the manuscript to ensure
  clarity, consistency, and scientific accuracy.
- 899 Rakhila M-Conducted the data analysis, molecular docking simulations, and statistical
- 900 interpretation of the results and edited the manuscript to ensure clarity, consistency, and 901 scientific accuracy.
- 902 Ayisha Safeeda- Conducted the data analysis, molecular docking simulations, and statistical
- 903 interpretation of the results and edited the manuscript to ensure clarity, consistency, and 904 scientific accuracy.
- 905 Satheesh S -was responsible for creating and editing the figures and tables that visually
- 906 represented the key findings.
- 907
- 908 Additional Information
- 909 Competing Interests
- 910 The authors declare no competing interests.
- 911
- 912 Figure Legends
- 913

**Fig. 1.** Representative HPLC chromatogram of crude and isolated samples R1, R2 and R3. **a** 

915 RP HPLC of Chromatogram of crude extract of *Streptomyces* sp. R2. **b** RP HPLC analysis

916 of mixture of R1, R2, R3. c RP HPLC of Chromatogram of pure Transitmycin R1. d

- 917 Transitmycin R1 obtained after column chromatographic purification. e UV-Vis spectra of
- 918 Transitmycin R1, R2 and R3. **f** IR Spectrum of Transitmycin R1.
**Fig. 2** Notable characteristic <sup>1</sup>H NMR spectra of different proline units of Transitmycin as **a** 

920 R1 (4-oxoproline). **b** R2 (proline) and **c** R3 (4-OH proline). **d** Comparative studies for  ${}^{1}$ H

- 921 NMR (500 MHz, CDCl<sub>3</sub>) chemical shift value of NH containing amino acid residue and
- 922 chromophore motifs of Transitmycin (R1), R2 and R3.
- Fig. 3. a Key <sup>1</sup>H-<sup>1</sup>H COSY correlation of Transitmycin (R1). b Key <sup>1</sup>H-<sup>1</sup>H TOCSY
  correlation of Transitmycin (R1). c Key <sup>1</sup>H-<sup>13</sup>C HMBC connectivity for Transitmycin (R1).
  c <sup>1</sup>H-<sup>1</sup>H ROESY correlation of Transitmycin (R1). d Chemical structure of isolated
  compounds Transitmycin (R1). e R2. f R3.

927 Fig. 4 a-m. Comparative analysis of MALDI-TOF-MS for molecular ion peak of 928 Transitmycin (R1), R2, R3. a R1 (Simulated). b R2 (Simulated). c R3 (Simulated). d R1 929 (Measured, positive mode. e R2 (Measured, Positive mode). f R3 (Measured, Positive 930 mode). g R1 (Measured, Negative mode). h R2 (Measured, Negative mode). i R3 931 (Measured, Negative mode), MALDI-TOF-MS spectra of crude extract of *Streptomyces* sp. 932 R2. j positive mode. k negative mode l Comparative analysis for HR-ESI-MS and MALDI-933 TOF-MS of Transitmycin (R1), R2 and R3 on various batches. m Characteristic retention 934 factor (R<sub>f</sub>) value and corresponding HR-ESI-MS data of purified compounds (Transitmycin 935 (R1), R2 and R3).

936 Fig. 5. a Mass spectral fragmentation of Transitmycin (R1) obtained by MALDI-TOF-MS, 937 **b** MALDI-TOF-MS spectrum of Transitmycin (R1). **c** Mass spectral fragmentation of 938 Transitmycin (R1) obtained by MALDI-TOF-MS, 211-  $\beta$ -Ring-Val-Oxo-Pro, 233-  $\alpha$  -Ring-939 Val-Pro, 294-β-Ring-Oxo-Pro-Sar-NMeVal, 295-Chromophore, 297- β-Ring-Thr-Val-Oxo-Pro, 357-α-Ring-Val-Pro-Sar-MeVal, 371-β-Ring-Val-Oxo-Pro-Sar-MeVal, 412-β-Ring-940 941 Val-Oxo-Pro-Sar-NMeVal, 412-α-Ring-Val-Pro-Sar-NMeVal+859 (Y ion), 495-β-Ring-942 Thr-Val-Oxo-Pro-Sar-NMeVal, 496-α-Ring-Thr-Val-Pro-Sar-NMeVal, 464 α - Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 746-Y-113 (MeVal), 747- a-Ring-Val-Pro-Sar-NMeVal+Y-943 944 MeVal+545.6,  $495 = \beta$ -Ring-Thr-Val-Oxo-Pro-Sar-NMeVal, 495-371=124-23=101 MeVal 945 (β-Ring-Thr-Val-Oxo-Pro-Sar), 371(β-Ring-Thr-Val-Oxo-Pro-Sar), 294 (β-Ring-Thr-Val-946 Oxo-Pro).

947

Fig. 6. a HPLC data analysis for L-FDAA derivatives to hydrolysates of Transitmycin R1
and standard amino acids. b Graphical representation for RP-HPLC chromatogram of L-

950 FDAA (Marfey's) derivatives of hydrosylated Transitmycin (R1). c HR-LCMS data analysis

- 951 for L-FDAA derivatives to hydrolysates of Transitmycin R1 and standard amino acids.
- 952

**Fig. 7.** MIC of Transitmycin in micrograms per millilitre for *Mycobacterium tuberculosis* isolates susceptible to anti-TB drugs (n=49) and drug resistant to one or more anti-TB drugs (n=48) as determined by LRP assay. Sensitive strains are represented in blue colour and resistant strains are represented in brown colour.

957

958 Fig. 8 a Activity of Transitmycin against different HIV-1 clades. Various concentrations of 959 Transitmycin were tested using 100 TCID<sub>50</sub> of virus belonging to 6 different HIV-1 clades as 960 well as two drug-resistant strains. Each concentration was tested in triplicate on all the 961 indicated viruses and mean  $\pm$  SEM values are shown in the graph. Log<sub>10</sub> -2 in the figure 962 equals 0.01  $\mu$ g/ml, Log<sub>10</sub> -1 equals 0.1  $\mu$ g/ml, Log<sub>10</sub> 0 equals 1  $\mu$ g/ml and Log<sub>10</sub> 1 equals 10 963 µg/ml. b Activity of Transitmycin on clinical isolates obtained from HIV-1 infected 964 individuals. Three concentrations of Transitmycin and two concentrations of AZT were 965 tested against 20 clinical isolates and mean + SD values are shown on the graph. This 966 experiment was performed on two different occasions.

967

**Fig. 9** a) R1, b) R2 and c) R3 binds with the DNA and emit fluorescence in a dose dependent manner. The concentrations of R1, R2 and R3 tested were 0.5  $\mu$ g/ml, 1  $\mu$ g/ml, 2  $\mu$ g/ml and 5  $\mu$ g/ml. As the concentration increases, the Relative fluorescence unit (RFU) also increases.

972

973 Fig 10. a) Transitmycin structure b) Chromophore part of transitmycin or its derivatives,
974 c) 1MNV R2 Docking Pose d) 3PKE with R3 Docking pose e) RMSD values of Residues
975 during the simulation Plot (3PKE with R3).

- 976
- 977 Table Legends
- 978

979 Table 1. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>)/<sup>13</sup>C NMR (125 MHz, CDCl<sub>3</sub>) and 2D NMR (500

980 MHz, CDCl<sub>3</sub>) correlation spectral data of Transitmycin (R1)  $^{1}$  H $^{-1}$  H COSY,  $^{1}$ H $^{-1}$ H TOCSY

- 981  ${}^{1}\text{H}{-}^{13}\text{C}$  HMBC,  ${}^{1}\text{H}{-}^{1}\text{H}$  ROESY
- 982 **Table 2.** Physico-chemical properties of Transitmycin.

- **Table 3.** Activity of transitmycin on biofilm formation.
- **Table 4**. The docking score data of specific target (1MNV, 3PKE, 1MO3, 3IU8) and three ligands: R1, R2, and R3

#### 986 References

- 9871. Abdelmohsen UR, Potential of marine natural products against drug-resistant fungal, viral,
- 988 and parasitic infections. *Lancet Infect. Dis.* 2017;17: e30–e41.
- 2. Quan D, et al. New tuberculosis drug leads from naturally occurring compounds. <u>Int. J.</u> <u>Infect. Dis.017;56:212-220.</u>
- 9913. Shin HJ, Kwon JS. Treatment of Drug Susceptible Pulmonary Tuberculosis. *Tuberc. Respir.*992 *Dis.2015;* 78:161-167.
- 4. <u>Tran</u> T, et al. Sansanmycin natural product analogues as potent and selective antimycobacterials that inhibit lipid I biosynthesis. *Nature Commun.* 2017; 8:14414.
- 5. Sotgiu G. *et al.* Tuberculosis Treatment and Drug Regimens. Cold Spring Harb Perspect Med 2015;5: a017822.
- 9976. Igarashi M, et al. New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development. *J. Antibiot.2018*;71:15–25.
- 9997. UNAIDS Report, (2017)
- 10008. Schader SM, Wainberg MA. Insights into HIV-1 pathogenesis through drug discovery: 30
  1001 years of basic research and concerns for the future. *HIV AIDS Rev.* 2011; 10:91–98.
- 10029. Parveen M, et al. Anti-HIV Drug Discovery Struggle: From Natural Products to Drug
- 1003 Prototypes. In Natural Products in Clinical Trials. Publisher: Bentham Science Publishers1004 (2018).
- 100510. Huang T, Lin S, Microbial Natural Products: A Promising Source for Drug Discovery. J.1006 Appl. Microbiol. Biochem. 2017;1:5.
- 100711. Barka EA, *et al.* Taxonomy, physiology, and natural products of *Actinobacteria.Microbiol.*1008 *Mol. Biol. Rev.2016*:80;1–43.
- 100912. Berdy J, Thoughts and facts about antibiotics: Where we are now and where we are heading. *J. Antibiot.2012*;65:385-395.
- 13. Velho-Pereira, SKamat, NM. Actinobacteriological research in India. *Indian J. Exp. Biol.* 2013; 51:573–596.
  - Balagurunathan R, et al. Extremophilic and extremotolerantActinomycetes: Distribution and Importance. In: Recent Trends in Microbial Diversity and Bioprospecting. Westville Publishing House, New Delhi (ISBN: 978-93-83491-14-8); 2014: pp. 114-128.

1013

- 15. <u>Dhakal</u> D, et al. Marine Rare Actinobacteria: Isolation, Characterization, and Strategies for Harnessing Bioactive Compounds. *Front Microbiol.* 2017;8:1106.
- 101516. <u>Genilloud O</u>, Actinomycetes: still a source of novel antibiotics. <u>Nat. Prod. Rep.</u> 2017;34:
  1016 1203-1232.
- 101717. Lam, KS. Discovery of novel metabolites from marine actinomycetes. *Curr. Opin.*1018 *Microbiol.* 2006:9;245-251.
- 101918. Raveh A, et al. Discovery of potent broad-spectrum antivirals derived from marine actinobacteria. *PLoS ONE*. 2013;8: e82318.
- 102119. Valliappan K, et al. Marine actinobacteria associated with marine organisms and their
  1022 potentials in producing pharmaceutical natural products. *Appl. Microbiol.*1023 *Biotechnol.* 2014:98;7365–7377.

102420. <u>Blunt JW</u>, et al. Marine natural products. <u>Nat. Prod. Rep</u>.2018;35:8-53.

102521. <u>Sarkar S</u>, et al. Enhanced production of antimicrobial compounds by three salt-tolerant 1026 actinobacterial strains isolated from the Sundarbans in a niche-mimic bioreactor. *Mar*.

- 1027 *Biotechnol*.2008;10:518-526.
- 102822. Saha M, et al. Production and purification of a bioactive substance inhibiting multiple drug
- 1029 resistant bacteria and human leukemia cells from a salt-tolerant
- 1030 marine Actinobacterium sp. isolated from the Bay of Bengal. Biotechnol. Lett. 2006;
- **1031** 28:1083–1088.
- 103223. Tindall BJ, et al. Notes on the characterization of prokaryote strains for taxonomic purposes.1033 *Int. J. Syst. Evol. Microbiol.* 2010; 60:249e266.
- 103424. Shirling EB, & Gottileb D. Methods for characterization of *Streptomyces* species. *Int. J.*1035 *Syst. Bacteriol.*16, 313-340 (1966).
- 103625. Nonomura H. Key for classification and identification of 458 species of the *Streptomyces*1037 included in ISP. *J. Ferment. Technol.* 1974; 52:78-92.
- 103826. Labeda DP, Shearer MC. Isolation of actinomycetes for biotechnological applications. In

1039 Isolation of Biotechnological Organisms from Nature, D.P. Labeda, Ed., 1990;19:1–19,

- 1040 McGraw-Hill, New York, NY, USA.
- 104127. Konstantinidis KT, Tiedje JM. Genomic insights that advance the species definition for 1042 prokaryotes. *Proc. Natl. Acad. Sci.* 2005; 102:2567-2572.
- 104328. Stackebrandt E, et al. Report of the ad hoc committee for the reevaluation of the species
- definition in bacteriology. Int. J. Syst. Evol. Microbiol.2002;52:1043-1047.

104529. Gopikrishnan V, et al. Quercetin from marine derived Streptomyces fradiae PE7:

- 1046 Taxonomy, fermentation, antifouling activity and characterization. *Environ. Sci. Pollut. Res.*
- 1047 *Int.* 2016; 23:13832-13842.
- 104830. Pazhanimurugan R, et al. Terpenoid bioactive compound from Streptomyces rochei (M32):
- 1049 Taxonomy, fermentation and biological activities. *World. J. Microbiol. Biotechnol.* 2016;31:1050 161.
- 105131. Manteca A, et al. Mycelium differentiation and antibiotic production in submerged cultures
  of *Streptomyces coelicolor*. *Appl. Environ. Microbiol.*2008;74:3877-3886.
- 105332. Shomura T, et al. Studies on actinomycetales producing antibiotics only on agar culture I.
- 1054 Screening, taxonomy and morphological productivity relationship of *Streptomyces halstedii*
- 1055 strain SF-1993. J. Antibiot. 1979; 32:427-435.
- 105633. Mayurama HB, et al. A new antibiotic, fumaridmycin. I. Production, biological properties
- and characterization of producer strain. J. Antibiot.1975;28:636-647.

105834. Ohnishi Y, et al. Structures of Grixazone A and B, A-factor dependent yellow pigments

- 1059 produced under phosphate depletion by *Streptomyces griseus*. J. Antibiot.2004;57:218-223.
- 106035. Conti F, De Santis P. Conformation of Acitinomycin D. Nature. 1070; 227:191239-1241. 1061
- 106236. Ulrich Hollstein, Actinomycin. Chemistry and Mechanism of Action, Chemical Reviews,1063 1974, 74;6.625-652.
- 1064
- 106537. AB. Mauger, WA. Thomas, NMR Studies of Actinomycins Varying at the Proline Sites,
  0066 ORGANIC MAGNETIC RESONANCE, 1981;17:3,1981.
  1067
- 106838. Yu C, Tseng YY. NMR study of the solution conformation of actinomycin D. Eur. J.
  1069 Biochem. 1992; 209:181–187. <u>https://doi.org/10.1111/j.1432-1033.1992.tb17275.x</u>.
- 1070
- 107139. Shigehiro K, Fusao T. Multiple Binding Modes of Anticancer Drug Actinomycin D:X-ray,
  1072 Molecular Modeling, and Spectroscopic Studies of d (GAAGCTTC)2-Actinomycin D
  1073 Complexes and Its Host DNA, *J. Am. Chem. SOC.* 1994;116:41544165.
- 1074
- 107540. Helmut L, Isabel B, Nobuharu S, Lewis KP, Anthony B. Mauger. Structures of Five 1076 Components of the Actinomycin Z Complex from *Streptomyces fradiae*, Two of Which 1077 Contain 4-Chlorothreonine. *J. Nat. Prod.* 2000; *63:352-356*.
- 1078
- 107941. Jens B, Victoria G, Axel Z, Actinomycins with Altered Threonine Units in the *â*-1080 Peptidolactone, *J. Nat. Prod.* 2006;69:1153-1157.
- 1081

108242. Bitzer J, Streibel M, Langer, HJ, Grond S. First Y-type actinomycins from Streptomyces
with divergent structure-activity relationships for antibacterial and cytotoxic properties. Org.
Biomol. Chem. 2009; 7:444–450.

1085

108643. Lackner H, Bahner I, Shigematsu N, Pannell LK, Mauger, AB. Structures of five
components of the actinomycin Z complex from Streptomyces fradiae, two of which contain
4-chlorothreonine. J. Nat. Prod. 2000; 63:352–356. https://doi.org/10.1021/np990416u.

- 109044. Caixia C, Fuhang S, Qian W, Wael M, Abdel M, HuiGuo, Chengzh F, Weiyuan H,
  1091 Huanqin D Xueting L Na Yang, FengXie, Ke Yu, Ruxian Chen, Lixin Zhang, A marine1092 derived Streptomyces sp. MS449 produces high yield of actinomycin X2 and actinomycin D
- 1093 with potent anti-tuberculosis activity. Appl Microbiol Biotechnol. 2012; 95:919–927.
- 1094
- 109545. Xiaoling W, Jioji Tabudravu Mostafa Ezzat Rateb, Krystal JA, Zhiwei Q, Marcel J, Zixin D,
  Yi Yband, Hai D, Identification and characterization of the actinomycin G gene cluster in
  Streptomyces iakyrus. *Mol. BioSyst.* 2013: 9:1286–1289.
- 1098

109946. Xiufang Zhang, Xuewei Ye, Weiyun Chai, Xiao-Yuan Lian, and Zhizhen Zhang, New

1100

110147. Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338,

1102 Mar. Drugs 2016;14:181.

110348. Machushynets, NV, Elsayed, SS, Du C. et al. Discovery of actinomycin L, a new member
of the actinomycin family of antibiotics. Sci Rep 2022; 12:2813.
<u>https://doi.org/10.1038/s41598-022-06736-0</u>.

1106

110749. Wang Q, Zhang Y, Wang M. et al. Neo-actinomycins A and B, natural actinomycins bearing the 5H-oxazolo[4,5-b] phenoxazine chromophore, from the marine-derived Streptomyces sp. IMB094. Sci Rep. 2017; 7: 3591. https://doi.org/10.1038/s41598-017-03769-8.

1111

111250. Qureshi KA, Bholay, AD, Rai PK. et al. Isolation, characterization, anti-MRSA evaluation,

and in-silico multi-target anti-microbial validations of actinomycin X2 and actinomycin D

1114 produced by novel Streptomyces smyrnaeus UKAQ\_23. Sci Rep. 2021; 11:14539.

1115 https://doi.org/10.1038/s41598-021-93285-7.

1116

111751. Zhang Z, Peng G, Yang G, Xiao CL, Hao XQ (2009) Isolation, purification, identification 1118of structures and study of bioactivity of anti-TB active component 9005B. Chin J Antibiot 111934:399–402.

1120

112152. Roboz, J Nieves E, Holland JF. McCamish, M, Smith C. Collisional ActivationDecomposition of Actinomycins Using Tandem Mass Spectrometry BIOMEDICAL AND

1123 ENVIRONMENTAL MASS SPECTROMETRY, 1988;16:67-70.

1124

- 112553. Darren T, Michael M, Jonathan M. Curtis R, K. Boyd K, Fragmentation Mechanisms of
- 1126 Protonated Actinomycins and Their Use in Structural Determination of Unknown
- 1127 Analogues, JOURNAL OF MASS SPECTROMETRY.1995;30:1111-1125.
- 1128 54. Rebecca H. Wills, Peter BO. Connor Structural Characterization of Actinomycin D
- 1129 Using Multiple Ion Isolation and Electron Induced Dissociation J. Am. Soc. Mass Spectrom.
- **1130** 2014; 25:186Y195.
- 1131 55. Benzel J, Bajraktari-Sylejmani, G. Uhl, P. Davis A, Nair S, Pfister SM, Haefeli WE,
- 1132 Weiss J, Burhenne J, Pajtler, KW. Sauter M. Investigating the Central Nervous System
- 1133 Disposition of Actinomycin D: Implementation and Evaluation of Cerebral Microdialysis and
- 1134 Brain Tissue Measurements Supported by UPLC-MS/MS Quantification. Pharmaceutics
- 1135 2021; 13:1498. https://doi.org/10.3390/pharmaceutics13091498.
- 1136 56. Vater J, Crnovčić I, Semsary S, Keller U. MALDI-TOF mass spectrometry, an efficient
- 1137 technique for in situ detection and characterization of actinomycins. J Mass Spectrom. 2014
- 1138 ;49(3):210-22. doi: 10.1002/jms.3329. PMID: 24619547.
- 1139 57. Crnovčić I, Vater, J. Keller, U. Occurrence and biosynthesis of C-demethylactinomycins
- 1140 in actinomycin-producing Streptomyces chrysomallus and Streptomyces parvulus. J Antibiot,
- 1141 2013;66:211–218. https://doi.org/10.1038/ja.2012.120.
- 114258. Singh, M. P. et al. Mannopeptimycins, new cyclic glycopeptide antibiotics produced by
- 1143 *Streptomyces hygroscopicus*LL-AC98: Antibacterial and mechanistic activities. *Antimicrob*.
- 1144 Agents Chemother.2003;47:62-69.

114559. Maskey. R. P. et al. Chandranainmycins A-C: Production of novel anticancer antibiotics

- 1146 from a marine Actinomadura sp. Isolate M)-48 by variation of medium composition and
- growth conditions. J. Antibiot. 2003; 57:1-7.
- 114860. Marfey, P. Determination of D-amino acids. II. Use of a bifunctional reagent, 1,5-difluoro-11492,4-dinitrobenzene. Carlsberg Res. Commun. 1984; 49:59. <u>https://doi.org/10.1007/BF02908688</u>. 1150
- 115161. Kochhar S. and Christen P. Amino acid analysis by high-performance liquid 1152chromatography after derivatization with 1-fluoro-2, 4-dinitrophenyl-5-L-ala-nine amide. *Anal.* 1153*Biochem.* 1989; 178:17–21.
- 1154
- 115562. Goodlett DR, Abuaf PA, Savage PA, Kowalski K.A, Mukherjee TK. Tolan JW., et al. 1156Peptide chiral purity determination: hydrolysis in deuter-ated acid derivatization with Marfey's 1157reagent and analysis using high-performance liquid chromatography-electrospray ionization-1158mass spectrometry. J. Chromatog. 1995; A707:233–244.
- 116063. Ken-ichi H, Kiyonaga F, Tsuyoshi M, Yasuko H, Makoto S, Yoshitomo I, Hisao O, A 1161method usingL/CMS for determination of absolute configuration of constituent amino acids in 1162peptide --- advanced Marfey's method.,Tetrahedron Letters, 1995;36:9,1515-1518. 1163

116464. Ayon NJ, Sharma AD, Gutheil WG. LC-MS/MS-Based Separation and Quantification of 1165Marfey's Reagent Derivatized Proteinogenic Amino Acid DL-Stereoisomers. J Am Soc Mass 1166Spectrom. 2019;30(3):448-458.

1167

116865. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC

1169 BY-NC-SA 3.0 IGO.

117066. Chiarelli, L. R. et al. A multi target approach to drug discovery inhibiting Mycobacterium

1171 *tuberculosis* PyrG and PanK. *Nature Sci. Rep.* 2018:8;3187.

117267. Heo, J. et al. High-content screening of raw actinomycete extracts for the identification of

antituberculosis activities. *SLAS Discovery*. 2017; 22:144-154.

117468. Bu Y. Y. et al. Anti-mycobacterial nucleoside antibiotics from a marine-derived
1175 Streptomyces sp. TPU1236A. Mar. Drugs. 2014;12: 6102-6112.

69. <u>Chen, C</u>. et al. A marine-derived *Streptomyces* sp. MS449 produces high yield of actinomycin X2 and actinomycin D with potent anti-tuberculosis activity. <u>Appl. Microbiol.</u>

<u>Biotechnol.</u> 2012;95:

117970. Dalton JP, et al. Effect of common and experimental anti-tuberculosis treatments on
Mycobacterium tuberculosis growing as biofilms. *Peer J.* 2016;4: e2717.

118171. Narendran G, Swaminathan, S. TB–HIV co-infection: a catastrophic comradeship. *Oral Dis.2016*; 22:46–52.

118372. Xu LH, et al. Actinomycete Systematics – Principles, Methods, and Practice. Science Press:Beijing (2007).

118573. Bauer AW, Kirby, WMM. Antibiotic susceptibility testing by a standardized single disc method. *American J. Clin. Pathol.* 1966; 45:493-496.

118774. Staneck JL, Roberts GD. Simplified Approach to Identification of Aerobic Actinomycetesby Thin-Layer Chromatography. *Appl. Microbiol.1974*;28:226-231.

118975. Kimura MA, simple method for estimating evolutionary rates of base substitutions throughcomparative studies of nucleotide sequences. *J. Mol. Evol.* 1980:16:111–120.

119176. Eccleston GP, et al. The occurrence of bioactive micromonosporae in aquatic habitats of theSunshine Coast in Australia. *Mar. Drugs.2008*;6: 243–261.

119377. Radhakrishnan M, et al. Preliminary screening for antibacterial and antimycobacterial
activity of actinomycetes from less explored ecosystems. *World J. Microbiol. Biotechnol.2010*;26:561-566.

119678. Harindran J, et al. HA-1-92, A new antifungal antibiotic produced by Streptomyces CDRIL-

1197 312: fermentation, isolation, purification and biological activity. World J. Microbiol.

*Biotechnol.1999*;15:425-430.

119979. Augustine SK, et al. A non-polyene antifungal antibiotic from *Streptomyces albidoflavus* PU23. *J. Biosciences*. 2005:30201-211.

120180. <u>Ojha</u> AK, et al. Growth of *Mycobacterium tuberculosis* biofilms containing free mycolic
1202 acids and harbouring drug-tolerant bacteria. *Mol. Microbiol.2008*;69:164–174.

- 120381. Arumugam, G.S., et al. Significant perspectives on various viral infections targeted antiviral
- 1204 drugs and vaccines including COVID-19 pandemicity. *Mol Biomed* 3, 21 (2022).
   1205 <u>https://doi.org/10.1186/s43556-022-00078-z</u>

120682. Mondal R, et al. (2023) In-vivo studies on Transitmycin, a potent *Mycobacterium*1207 *tuberculosis* inhibitor. PLoS ONE 18(3): e0282454.
1208 https://doi.org/10.1371/journal.pone.0282454.

# Discovery of a novel antibiotic, Transitmycin, from *Streptomyces* sp unveils highly efficient activities against tuberculosis and human immunodeficiency virus

Vanaja Kumar<sup>\*1,4</sup>, Balagurunathan Ramasamy<sup>2</sup>, Mukesh Doble <sup>\$3,5</sup>, Radhakrishnan Manikkam<sup>4</sup>, Luke Elizabeth Hanna<sup>1</sup>, Gandarvakottai

Senthilkumar Arumugam<sup>3.7</sup>, Kannan Damodharan<sup>3</sup>, Suresh Ganesan<sup>3</sup>, Azger Dusthakeer<sup>1</sup>, Precilla Lucia<sup>1</sup>, Shainaba A Saadhali<sup>1</sup>, Shanthi John<sup>2</sup>,

Poongothai Eswaran<sup>2</sup>, Selvakumar Nagamiah<sup>1</sup>, Jaleel UCA<sup>6</sup>, Rakhila M<sup>6</sup>, Ayisha Safeeda<sup>6</sup> and Sathish S<sup>6</sup>

<sup>1</sup>National Institute for Research in Tuberculosis, Chennai – 600031, Tamilnadu, India

<sup>2</sup>Department of Microbiology, Periyar University, Salem – 636011, Tamilnadu, India

<sup>3</sup>Department of Biotechnology, Indian Institute of Technology, Madras - 600036, Tamilnadu, India

<sup>4</sup>Centre for Drug Discovery and Development, Sathyabama Institute of Science and Technology

(Deemed to be University), Chennai - 600119, Tamilnadu. India

<sup>5</sup> Saveetha Dental College and Hospitals, 62, Poonamallee High Rd, Chennai, 600077, India

<sup>6</sup>Open Source Pharma Foundation-National Institute of Advanced Studies Drug Discovery Lab, NIAS, IISc Campus, Bangalore, Karnataka, India

<sup>7</sup>SSS International Drug Discovery & Development Research Private Limited, Innovation & Entrepreneurship, Sudha & Shankar innovation hub, IIT Madras,-600036

Chennai, India

Email: \*vanaja\_kumar51@yahoo.co.in; \$ mukeshdoble.sdc@saveetha.com

#### **Corresponding Author:**

Dr. Vanaja Kumar

Former Scientist G & Head

Department of Bacteriology

<sup>1</sup>National Institute for Research in Tuberculosis,

Chennai - 600 031. Tamil Nadu. India

Email: vanaja\_kumar51@yahoo.co.in

## **Supplementary Information**

	Title	Page Number
S-Table 1.	Phenotypic characteristics of Streptomyces sp. R2	S10
S-Table 2.	Effect of solvents on the extraction of Transitmycin	S11
Figure S1	Characteristic microbial strain and its morphological arrangement	S12
Figure S1a	(a) TLC of Ethyl acetate extract of Streptomyces sp R2 in UV light (b) Long UV (c) Short UV	S13
Figure S2.	Purification of EA extract of Streptomyces sp. R2 by Preparative Thin-Layer Chromatography	S14
Figure S3.	Scheme of purification of EA extract of Streptomyces sp. R2 by Column Chromatograph	S15
Figure S4.	RP HPLC of the ethyl acetate extract of Streptomyces sp. R2 (Batch II)	S16
Figure S5.	Purity of Transitmycin R1, R2, R3 were checked by RP HPLC method	S17
S-Table 3.	HPLC Retention time of R1, R2, R3	S17
Figure S6.	UV/Vis Spectrum of R2 in methanol	S18
Figure S7.	UV/Vis Spectrum of R3 in methanol	S19
Figure S8.	Circular Dichroism Spectrum of Transitmycin (R1) in methanol	S20
Figure S9.	Circular Dichroism Spectrum of R2 in methanol	S21
Figure S10.	Circular Dichroism Spectrum of R3 in methanol	S22
Figure S11.	FT-IR Spectrum of Transitmycin (R1), R2, R3	S23
Figure S12.	FT-IR Spectrum of R2	S24
Figure S13.	FT-IR Spectrum of R3	S25
Table S4.	IR Absorption Frequencies of Functional Groups Present in R1, R2, R3	S26
Figure S14.	<sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S27
Figure S15.	Expansion of <sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S28
Figure S16.	Expansion of <sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S29
Figure S17.	Expansion of <sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S30
Figure S18.	Expansion of <sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S31

Figure S19.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S32
Figure S20.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S33
Figure S21.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S34
Figure S22.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S35
Figure S23	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S36
Figure S24.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S37
Figure S25.	<sup>13</sup> C-NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S38
Figure S26.	DEPT135 (125 MHz CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S39
Figure S27.	COSY (500 MHz) Spectrum of Transitmycin (R1)	S40
Figure S28.	DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S41
Figure S29.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S42
Figure S30.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1	S43
Figure S31.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S44
Figure S32.	Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)	S45
Figure S33.	HMBC (500 MHz) Spectrum of Transitmycin (R1)	S46
Figure S34.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S47
Figure S35.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S48
Figure S36.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1	S49
Figure S37.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S50
Figure S38.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S51
Figure S39.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S52
Figure S40.	Expansion of HMBC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S53
Figure S41.	HSQC (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S54
Figure S42.	TOCSY (500 MHz) Spectrum of Transitmycin (R1)	S55
Figure S43.	Expansion of TOCSY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S56

Figure S44.	Expansion of TOCSY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S57
Figure S45.	Expansion of TOCSY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S58
Figure S46.	NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S59
Figure S47.	Expansion of NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S60
Figure S48.	Expansion of NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S61
Figure S49.	Expansion of NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S62
Figure S50.	Expansion of NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S63
Figure S51.	Expansion of NOESY (500 MHz, CDCl <sub>3</sub> ) Spectrum of Transitmycin (R1)	S64
Figure S52.	ROESY (500 MHz) Spectrum of Transitmycin (R1)	S65
Table S5.	NMR data of Transitmycin (R1) in CDCl <sub>3</sub> ( <sup>1</sup> H: 500 MHz <sup>13</sup> C: 125 MHz)	S66-72
Figure S53.	<sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Compound R2	S73
Figure S54.	<sup>13</sup> C NMR (125 MHz, CDCl <sub>3</sub> ) Spectrum of Compound R 2	S74
Figure S55.	DEPT135&90 (125 MHz CDCl <sub>3</sub> ) Spectrum of Compound R2	S75
Figure S56.	Expansion of DEPT135 & 90 (125 MHz, CDCl <sub>3</sub> ) Spectrum of Compound R2	S76
Figure S57.	Expansion of DEPT135 & 90 (125 MHz, CDCl <sub>3</sub> ) Spectrum of Compound R2	S77
Figure S58.	COSY (500 MHz) Spectrum of Compound R2	S78
Figure S59.	DQF-COSY (500 MHz) Spectrum of Compound R2	S79
Figure S60.	HMBC (500 MHz) Spectrum Compound of R2	S80
Figure S61.	HSQC (500 MHz) Spectrum of Compound R2	S81
Figure S62.	TOCSY (500 MHz) Spectrum of Compound R2	S82
Figure S63.	NOESY (500 MHz) Spectrum of Compound R2	S83
Figure S64.	<sup>1</sup> H-NMR (500 MHz, CDCl <sub>3</sub> ) Spectrum of Compound R3	S84
Figure S65.	DQF-COSY (500 MHz) Spectrum of Compound R <sub>3</sub>	S85
Figure S66.	HMBC (500 MHz) Spectrum of Compound R3	\$86
Figure S67.	HSQC (500 MHz) Spectrum of Compound R3	\$87

Figure S68.	TOCSY (500 MHz) Spectrum of Compound R3	S88
Figure S69.	NOESY (500 MHz) Spectrum of Compound R3	S89
Figure S70.	MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)	S90
Figure S71.	Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak)	
Figure S72.	Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak	S92
Figure S73.	MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)	<b>S</b> 93
Figure S74.	Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)	S94
Figure S75.	Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (Negative mode)	S95
Figure S76.	MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (positive mode)	<b>S</b> 96
Figure S77.	MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (Negative mode)	S97
Figure S78.	MALDI-TOF MS Spectrum of Transitmycin (R1) (Positive mode)	S98
Figure S79.	MALDI-TOF MS Spectrum of Transitmycin A (Negative mode)	<b>S</b> 99
Table S6.	MALDI-TOF MS Spectral Fragmentation of Transitmycin (R1) (Positive mode)	S100
Figure S80.	MALDI-TOF MS Spectrum of R2 (Positive mode	S101
Figure S81.	MALDI-TOF MS Spectrum of R2 (Negative mode)	S102
Figure S82.	MALDI-TOF MS Spectrum of R3 (Positive mode)	S103
Figure S83.	MALDI-TOF MS Spectrum of R3 (Negative mode)	S104
Figure S84.	QTRAP MS/MS Transitmycin (R1) (Molecular ion peak) (Positive mode)	S105
Figure S85.	QTRAP MS/MS Transitmycin (R1) (Molecular ion peak [M+H] <sup>2+</sup> (Positive mode)	S106
Figure S86.	QTRAP MS/MS of Transitmycin (R1) (Molecular ion peak) (Negative mode)	S107
Figure S87.	QTRAP MS/MS of R2 (Molecular ion peak) ((Positive mode)	S108
Figure S88.	QTRAP MS/MS of R2 [M+H] <sup>2+</sup> ion peak (Positive mode)	S109
Figure S89.	QTRAP MS/MS of R2 (Molecular ion peak (Positive mode)	S100
Figure S90.	QTRAP MS/MS of R3 Molecular ion peak (Positive mode)	S111
Figure S91.	QTRAP MS/MS of R3 (Molecular ion peak (Negative mode)	S112
Figure S92.	HR-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)	S113
Figure S93.	HR-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion Peak) (Positive mode)	S114

Figure S94.	HR-ESI-MS Spectrum of R2 (Positive mode)	S115	
Figure S95.	HR-ESI-MS Spectrum of R2 (Molecular ion Peak) (Positive mode)	S116	
Figure S96.	HR-ESI-MS Spectrum of R3 (Positive mode)		
Figure S97.	HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)		
Figure S98.	LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)	S119	
Figure S99.	LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode).	S120	
Figure S100.	LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)	S121	
Figure S101.	LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)	S122	
Figure S102.	LC-ESI-MS Spectrum of R2 (Positive mode)	S123	
Figure S103.	LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)	S124	
Figure S104.	LC-ESI-MS Spectrum of R3 (Positive mode).	S125	
Figure S105.	Figure S105. LC-ESI-MS Spectrum of R3 (Positive mode)		
Figure S106.	EI-MS Spectrum of Transitmycin (R1) (Positive mode)	S127	
Figure S107.	EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)	S128	
Figure S108.	EI-MS Spectrum of (R2) (Positive mode)	S129	
Figure S109.	EI-MS Spectrum of (R3) (Positive mode)	S130	
Figure S110.	CHN analysis data of Transitmycin (R1), R2, R3	S131	
Figure S111.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)	S132	
Figure S112.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S133	
Figure S113.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S134	
Figure S114.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S135	
Figure S115.	3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)	S136	
Figure S115 a, b	Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS	S137	
Table S7a.	Structural characterisation of Transitmycin (R1) [M+H] <sup>+</sup> obtained by QTRAP LCMS/MS	S138	
Table S7b.	Structural characterisation of Transitmycin (R1) [M+Na] <sup>+</sup> obtained by QTRAP LCMS/MS	S139	
Figure S116.	Hydrolysis of amino acid residue of Transitmycin (R1), R2, R3	S140	
Figure S117a.	HPLC analysis of standard L-FDAA-D/L-Valine	S141a	

Figure S117b.	HPLC analysis of standard L-FDAA-D-Valine	S141b
Figure S117c.	HPLC analysis of standard L-FDAA-L-Valine	S141c
Figure S118 a.	HPLC analysis of standard L-FDAA-D/L-Proline	S142a
Figure S118 b.	HPLC analysis of standard L-FDAA-D-Proline	S142b
Figure S118c.	HPLC analysis of standard L-FDAA-L-Proline	S142c
Figure S119a.	HPLC analysis of standard L-FDAA-D/L-Threonine	S143a
Figure S119b.	HPLC analysis of standard L-FDAA-D-Threonine	S143b
Figure S119c.	HPLC analysis of standard L-FDAA-D-Threonine	S143c
Figure S120a.	HPLC analysis of standard L-FDAA-D/L-N-Methyl Valine	S144a
Figure S120b.	HPLC analysis of standard L-FDAA-D-N-Methyl Valine	S144b
Figure S120c.	HPLC analysis of standard L-FDAA-D-N-Methyl Valine	S144c
Figure S121a.	HPLC analysis of standard L-FDAA-D-Valine	S145a
Figure S121b.	HPLC analysis of standard L-FDAA-L-Valine	S145b
Figure S121c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of Transitmycin (R1)	S143a
Figure 122a.	HPLC analysis of standard L-FDAA-D-Valine	S143b
Figure S122b.	HPLC analysis of standard L-FDAA-L-Valine	S143c
Figure S122c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2	S144a
Figure S123a.	HPLC analysis of standard L-FDAA-D-Valine	S144b
Figure S123b.	HPLC analysis of standard L-FDAA-L-Valine	S144c
Figure S123c.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3	S145
Figure S124.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2	S148
Figure S125.	HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3	S149
Table 8a.	Analysis of L-FDAA derivates of acid hydrolysate of R2 by HPLC	S150
Table 8b.	Analysis of L-FDAA derivatives of acid hydrolysate of R3 by HPLC	S150
Figure S126.	ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)	S151
Figure S127.	ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)	S152
Figure S128.	LCMS analysis of Standard L-FDAA-D-Proline (Positive mode)	S153

Figure S129.	LCMS analysis of Standard L-FDAA-D-Proline (Negative mode)	S154
Figure S130.	LCMS analysis of Standard L-FDAA-L-Proline (Positive mode	S155
Figure S131.	LCMS analysis of Standard L-FDAA-L-Proline (Negative mode)	S156
Figure S132.	LCMS analysis of Standard L-FDAA-D/L-Proline (Positive mode)	S157
Figure S133.	LCMS analysis of Standard L-FDAA-D/L-Proline (Negative mode)	S158
Figure S134.	LCMS analysis of Standard L-FDAA-D-Valine (Positive mode)	S159
Figure S135.	LCMS analysis of Standard L-FDAA-D-Valine (Negative mode)	S160
Figure S136.	LCMS analysis of Standard L-FDAA-L-Valine (Positive mode)	S161
Figure S137.	LCMS analysis of Standard L-FDAA-L-Valine (Negative mode)	S162
Figure S138.	LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)	S163
Figure S139.	LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)	S164
Figure S140.	LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)	S165
Figure S141.	LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)	S166
Figure S142.	LCMS analysis of Standard L-FDAA-D-Threonine (Positive mode)	S167
Figure S143.	LCMS analysis of Standard L-FDAA-D-Threonine (Negative mode)	S168
Figure S144.	LCMS analysis of Standard L-FDAA-D/L Threonine (Positive mode)	S169
Figure S 145.	LCMS analysis of Standard L-FDAA-D/L Threonine (Negative mode)	S170
Figure S146.	LCMS analysis of Standard L-FDAA-D/L N-Methyl valine (Positive mode).	S171
Figure S147.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S172
Figure S148.	LCMS analysis of Standard L-FDAA-L N-Methyl valine (Positive mode)	S173
Figure S149.	LCMS analysis of Standard L-FDAA-L- N-Methyl valine (Positive mode)	S174
Figure S150.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S175
Figure S151.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S176
Figure S152.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Negative mode)	S177
Figure S153.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S178
Figure S154.	LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)	S179
Figure S155.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)	S180

Figure S156.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode).	S181
Figure S157.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)	S182
Figure S158.	LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode).	S183
Figure S159.	LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Positive mode)	S184
Figure S160.	LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Negative mode)	S185
Figure S161.	LCMS analysis of L-FDAA derivatives of R3 (Positive mode)	S186
Table S9a.	Analysis of L-FDAA derivates of acid hydrolysate of Transitmycin R1 by HPLC-MS	S187
Table S9b.	Analysis of L-FDAA derivates of acid hydrolysate of R3 by HPLCMS	S187
Table S10.	Physico-chemical properties of R2	S188-89
Table S11.	Physico-chemical properties of R3	S190-91
Table S12	Drug resistant profile of the clinical isolates of <i>Mycobacterium tuberculosis</i> used to determine the anti TB activity of Transitmycin	S192-194
Table S13	Anti-HIV activity of Transitmycin on various HIV-1 subtypes	S195

Characteristics	Results
Micromorphology	
Aerial mycelium	Present
Substrate mycelium	Present
Spore chain morphology	Rectus flexibile, non fragmented
Spore surface	Hairy
Cultural characteristics	
Colony consistency	Powdery
Aerial mass colour	Ash white
Reverse side pigment	Yellow
Soluble pigment	Yellow
Melanoid pigment	Absent
Growth on Different media	l
ISP1	Moderate
ISP2	Good
ISP3	Good
ISP4	Good
ISP5	Moderate
ISP6	Moderate
ISP7	Good
Carbon utilization	
Glucose	Good
Arabinose	Poor
Sucrose	Poor
Xylose	Moderate
Inositol	Poor
Mannitol	Good

S-Table 1. Phenotypic characteristics of Streptomyces sp. R2

Fructose	Moderate
Rhamnose	Moderate
Raffinose	No Growth
Cellulose	No Growth
pH tolerance	
5	No growth
7	Good
9	Good
11	Moderate
Growth at	
$20^{0}$ C	Poor
30 <sup>0</sup> C	Good
$40^{0}$ C	Good
$50^{0}$ C	Moderate
NaCl tolerance (%)	
0	Poor
1	Good
2.5	Good
5	Good
7.5	Poor
10	No growth
Susceptibility to	Tetracycline, chloramphenicol, erythromycin, gentamicin, vancomycin
Resistant to	Penicillin, nystatin, nalidixic acid

Solvents	Quantity of	Antibacterial activity	Anti TB activity
	extracts	against S. aureus	(% reduction in
		<b>MTCC 96</b>	RLU)
Methanol	40	14	58.31
Chloroform	41	9	18.07
Dichloromethane	40	13	22.71
Diethyl ether	10	14	74.23
Ethyl acetate	9	19	83.40
n-hexane	-	-	-

## S-Table 2. Effect of solvents on the extraction of Transitmycin



**Fig. S1**. Characteristic microbial strain and its morphological arrangement. **a** Cultural morphology and microscopic visualization. **b** SEM image (3,500X) of Streptomyces variabilis R2 on ISP2 agar medium. **c** Phylogenetic dendrogram obtained by distance matrix analysis of 16s rRNA gene sequences, showing the position of strain R2 among its phylogenetic neighbours.



Solvent system for TLC: Ethyl acetate /Methanol, (9.5:0.5)

**Rf** value of Transitmycin (**R1**) = 0.8

Rf value of R2 = 0.6

Rf value of R3 = 0.3

Solvent system for TLC: Ethyl acetate/Methanol, (9.5:0.5) (a) TLC of Ethyl acetate extract of Streptomyces sp. R2 in UV light (b) Long UV (c) Short UV





Solvent used for Preparative TLC: Ethylacetate:methanol, (9.5:0.5)

### Figure S2. Purification of EA extract of Streptomyces sp. R2 by Preparative Thin-Layer Chromatography

#### **Extraction and Isolation**

Purification of compounds were performed by preparative thin layer chromatography (TLC) using Merck silica gel 60 (GF254) pre coated aluminium (6x8 cm size) plates. The crude pigment was purified by using preparative thin layer chromatography commercially available pre coated silica gel chromatography sheets (6×8 cm size) were used. To find out the best solvent system to separate the crude compound, the solvents were used in different proportions, among all solvent systems used, Ethylacetate: methanol (9.5:0.5) showed good separation. The crude pigment (2 g) was dissolved in 5 mL of ethyl acetate. With the help of capillary tube, the sample was spotted at the bottom of silica gel coated sheet (6 x 8 cm) and then it was placed in the developing 100 mL beaker containing mobile phase (Ethyl acetate/ Methanol, 9.5:0.5) 5 mL, covered with the watch glass in order to prevent the evaporation of the solvents. The solvent was allowed to run till it reaches about half a centimetre below the top of the plate. After running, the 200 sheets were kept at room temperature for the complete drying of the plate. Spots on TLC were detected under UV light (254 and 365 nm) and by spraying with concentrated H<sub>2</sub>SO<sub>4</sub> followed by heating at 105 °C for 5 min. After drying, the yellow pigment spot was scrapped, mixed with ethyl acetate and filtered using funnel fitted with what man filtered paper and Ethyl acetate was evaporated to dryness under vacuum to afford the pure compound Transitmucin R1 (10 mg), R 2 (10 mg), R3 (5 mg). Rf value of the spot separated on the TLC plate was determined. The solvent system Ethyl acetate: methanol (9.5:0.5) was found to have good separation with single spot when compared to all the solvent systems used for TLC.



Column chromatography was carried out on Neutral Alumina (230-400 mesh) and Column size: (id  $30m \times 90$  cm). The crude ethyl acetate extract Streptomyces sp (R2) was purified using column chromatography packed with using alumina a gradient neutral of 1% Methanol/Chloroform mixture (CH<sub>3</sub>OH/ CHCl<sub>3</sub>) was used as the eluent. Fractions were collected and concentrated under vacuum to afford pure compounds. The desired product was monitored in a TLC with pre coated alumina sheet silica. The isolated compounds were obtained Transitmycin (R1) (200 mg), R2 (100 mg), R3 (50 mg).

**Figure S3 (a)** Crude (b) Crude with alumina (c) Before elution (d) After elution (e) solution form (f) solid form (g) After drying (h) TLC (i) **RP-HPLC** 



**S61** 

Figure S3. Scheme of purification of EA extract of *Streptomyces* sp. R2 by column chromatography



Figure S4. RP HPLC of the crude ethyl acetate extract of Streptomyces sp. R2 (Batch II)(2) 100 (150 X 4.6 mm) Solvent system: A: B (35: 65 v/v); flow rate 2 ml/min, 254 nm SolventA: Acetonitrile; Solvent B: Water,Detection: PDA, Injection volume: 20µl, Column Temperature: 30  $^{0}$ CA: Acetonitrile; Solvent B: Water,



## S-Table 3. RP-HPLC Retention time of R1, R2, R3

a	Ret. Time of R1	5.807 min
b	Ret. Time of R1	3.062 min
с	Ret. Time of R2	1.100 min





Figure S5. Purity of Transitmycin R1, R2, R3 were checked by RP HPLC method



Figure S6: UV/Vis Spectrum of R2 in methanol [UV: (MeOH) λ max, (log ε) 205, (1.25), 240 (0.63), 425 (0.39), 442(0.42) nm]



Figure S7. UV/Vis Spectrum of R3 in methanol [UV (MeOH) λ max (log ε) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) nm]



Figure S8. Circular Dichroism Spectrum of Transitmycin (R1) in methanol CD: [MeOH, [nm], (mdeg)]:  $\lambda_{max}(\Delta \epsilon)$  195 (+11.1), 210 (-21.0), 242 (+4.7)



Figure S9. Circular Dichroism Spectrum of R2 in methanol CD: [MeOH, [nm], (mdeg)]: λ<sub>max</sub>, (Δε) 195 (+8.8), 210 (-22.0), 240 (+4.3) nm



Figure S10. Circular Dichroism Spectrum of R3 in methanol CD: [MeOH, [nm], (mdeg)] λ<sub>max</sub>(Δε) 195 (+24.0), 210 (-21.5), 241 (+1.7)



Figure S11. FT-IR Spectrum of Transitmycin (R1), R2, R3



Figure S12. FT-IR Spectrum of R2



Figure S13. FT-IR Spectrum of R3

	IR (KBr cm <sup>-1</sup> ), 3435 cm <sup>-1</sup> for NH, 2958, 2924 cm <sup>-1</sup> (m, -CH str, asym, CH <sub>3</sub> and CH <sub>2</sub> ), 2872 cm <sup>-1</sup> , 2853 cm <sup>-1</sup> (m, -CH str, sym, CH <sub>3</sub> and CH <sub>2</sub> ), 1746
R1	cm <sup>-1</sup> (s, C=O str, lactone ring ), 1642 cm <sup>-1</sup> (s, -C=O str, 2 <sup>0</sup> amide), 1524, 1503 (m, -NH bend, 2 <sup>0</sup> amide), 1466 (m, CH bend (scissoring), CH <sub>2</sub> ),
	1379 cm <sup>-1</sup> (s, -CH bend, isopropyl group), 1268 (s, C-O str, ester), 1194 (C-O-C of lactone) 1099, 1059, 1017 (s, C-O or C-N), 720, 712, 694,
	689 (s, -CH bend, oop, aromatic ring), 909 (w, CH <sub>3</sub> rocking).
	IR (KBr cm <sup>-1</sup> ), 3436 cm <sup>-1</sup> for NH, 2961, 2924 cm <sup>-1</sup> (m, -CH str, asym, CH <sub>3</sub> and CH <sub>2</sub> ), 2872 cm <sup>-1</sup> , 2853 cm <sup>-1</sup> (m, -CH str, sym, CH <sub>3</sub> and CH <sub>2</sub> ), 1744
R2	cm <sup>-1</sup> (s, C=O str, lactone ring ), 1650 cm <sup>-1</sup> (s, -C=O str, 2 <sup>0</sup> amide), 1565, 1503 (m, -NH bend, 2 <sup>0</sup> amide), 1415 (m, CH bend (scissoring), CH <sub>2</sub> ), 1318
	cm <sup>-1</sup> (s, -CH bend, isopropyl group), 1268, 1204 (s, C-O str, ester),1140 (C-O-C of lactone), 1045, 1019 (s, C-O or C-N), 720, 712, 653 (s, -CH
	bend, oop, aromatic ring), 929 (w, CH <sub>3</sub> rocking).
	IR (KBr cm <sup>-1</sup> ), 3415 cm <sup>-1</sup> for NH, 2957, 2924 cm <sup>-1</sup> (m, -CH str, asym, CH <sub>3</sub> and CH <sub>2</sub> ), 2872 cm <sup>-1</sup> , 2853 cm <sup>-1</sup> (m, -CH str, sym, CH <sub>3</sub> and CH <sub>2</sub> ), 1745
R3	cm <sup>-1</sup> (s, C=O str, lactone ring ), 1642 cm <sup>-1</sup> (s, -C=O str, 2 <sup>0</sup> amide), 1583, 1507 (m, -NH bend, 2 <sup>0</sup> amide), 1464 (m, CH bend (scissoring), CH <sub>2</sub> ),
	1384, 1301 cm <sup>-1</sup> (s, -CH bend, isopropyl group), 1266, 1228 (s, C-O str, ester),1193 (C-O-C of lactone ),1093, 1078, 1017 (s, C-O or C-N), 909
	(w, CH <sub>3</sub> rocking) 720, 712, 694, 689 (s, -CH bend, oop, aromatic ring).

Г

## Table S4. IR Absorption Frequencies of Functional Groups Present in Transitmycin (R1), R2, R3


Figure S14. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S15. Expansion of <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S16. Expansion of <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S17. Expansion of <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S18. Expansion of <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S19. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)

110312_senthilkumar.2.fid R1	888	
9.01 3.3.95 3.12 3.12 5.12 5.12 5.12 5.12 5.12 5.12 5.12 5	25 C C C C C C C C C C C C C C C C C C C	50 50 50 50 50 50 50 50 50 50 50 50 50 5
	717777777777777777777777777777777777777	



Figure S20. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S21. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S22. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S23. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S24. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S25. <sup>13</sup>C-NMR (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S26. DEPT135 (125 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S27. COSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S28. DQF-COSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S29. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)



Figure S30. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)



Figure S31. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)



Figure S32. Expansion of DQF-COSY (500 MHz) Spectrum of Transitmycin (R1)



Figure 33. HMBC (500 MHz) Spectrum of Transitmycin (R1)



Figure S34. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S35. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S36. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S37. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S38. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S39. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S40. Expansion of HMBC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S41. HSQC (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S42. TOCSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S43. Expansion of TOCSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S44. Expansion of TOCSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S45. Expansion of TOCSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S46. NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S47. Expansion of NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S48. Expansion of NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S49. Expansion of NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)


Figure S50. Expansion of NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S51. Expansion of NOESY (500 MHz, CDCl<sub>3</sub>) Spectrum of Transitmycin (R1)



Figure S52. ROESY (500 MHz) Spectrum of Transitmycin (R1)

α- ring	position	δC	δH	J (Hz)	COSY	TOCSY	HMBC	ROSEY
Thr	1	168.8	-					
	2	54.6	4.60	d , 10.0	3, 4, -NH	3, 4	1, 3, 13	3, 4, 2-Val, Val-NH
	3	74.7	5.13	m	2, 4,- NH	2, 4,	4	2, 4, Val-NH
	4	17.0	1.10	d, 6.5	2, 3	2, 3, -NH	2, 3	2, 3, Val-NH
	NH	-	7.29	d, 7.0	2, 3, 4	2, 3, 4	1, 3, 13	2, 4
L-Val	1	173.4						
	2	58.7	3.58	dd, 10.5,6.5	3, 4, 5, - NH	3, 4, 5, - NH	1, 5, 1-Thr	3, 4, 5, 2-Pro
	3	31.7	2.08	m	2, 4, 5	2, 4, 5	2,5	4, 5, 4-Thr
	4	19.0	0.89	d, 7.0	2, 3	2, 3, -NH	2,3,5	2, 3, 5
	5	18.9	1.13	d, 6.5	2, 3	2, 3, -NH	2,3,4	2, 3, 2-Val, Val-NH
	NH	-	7.74	d, 5.5	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5 2- Thr, 3-Thr
Pro	1	173.1	-					
	2	56.4	5.93	d, 9.5	3a,3b,4a,4b	3a,3b 4a,	3, 4, 5,	3a, 3b,

Table S5: NMR data of Trasitmycin (R1) in CDCl3 (<sup>1</sup>H: 500 MHz <sup>13</sup>C: 125 MHz)

						4b	1-Val	2a-Sar,2b-Sar, Sar-NMe
	3	31.6	2.73 1.84	dd, 17.5,7.0 dd, 19.5,	3b, 4a, 4b 3a, 4a,	3b, 4a, 4b 3a, 4a,	1, 2, 4 1, 4, 5	3b, 2a-Sar, 2b-Sar 3a, 4a, 4b
	4	23.3	2.26 2.01	6.5 d, 16.5 d, 8.0	3a, 3b, 4b 3b, 4a	3a, 3b, 4b 3b, 4a	3, 5 3, 5	4b, 5a, 5b 4a, 5a
	5a 5b	47.8	3.86 3.67	d, 18.5 d, 18.5	3a, 4a, 4b 3a, 4a, 4b	3a, 4a, 4b 3a, 4a, 4b	4, 1-Val	5b
Sar	1	166.2	-					
	2	51.2	2a, 4.70 2b, 3.64	d, 17.5 d, 17.5	2b 2a	2b, NMe 2a, NMe	1, NMe,1- pro 1, NMe,1- Pro	2b, NMe, 2-Pro 4-MeVal, 5-MeVal, NMe
	N-Me	34.9	2.87	S		2a, 2b	2, 1-Pro	2b, 3-MeVal
MeVal	1	167.4	-					
	2	71.3	2.70	d, 9.0	3, 4, 5	3, 4, 5	1, 3,4,NMe	4, 5
	3	26.9	2.62	d, 7.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5

4	21.6	0.96	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
5	19.2	0.72	d, 6.5	2, 3	2, 3, 4	2, 3, 4	3
N-Me	39.2	2.89	S	-	2, 3	2, 1-Sar	2, 3, 5, 2a-Sar, 2b-Sar

β- ring	position	δC	δН	J (Hz)	COSY	TOCSY	НМВС	NOESY
Thr	1	168.9	-					
	2	54.9	4.50	d, 9.0	3,4, -NH	3, 4	1, 3, 14	3, 4, 2-Val, Val- NH
	3	74.6	5.23	m	2,4,- NH	2, 4	4	2,4, Val-NH
	4	17.6	1.20	d, 6.0	2, 3	2, 3, - NH	2, 3	2,3, Val-NH
	NH	-	7.68	d, 6.0	2, 3, 4	2, 3, 4	1, 3, 14	2, 4
L-Val	1	173.9	-					
	2	57.1	3.71	dd, 10.5, 6.5	3, 4, 5, -NH	3, 4, 5, -NH	1, 3, 5, 1-Thr,	3, 4, 5, 2-Oxo pro
	3	31.8	2.20	m	2, 4, 5	2, 4, 5	2, 5	4, 5, 4-Thr
	4	19.0	0.86	d, 7.0	2, 3	2, 3, -NH	2, 3, 5	2, 3, 5
	5	18.8	1.14	d, 7.0	2, 3	2, 3, -NH	2, 3, 4	2, 3, 2-Val, Val- NH
	NH		8.23	d, 6.0	2, 3, 4, 5	2, 3, 4, 5	2, 3, 1-Thr	2, 3, 4, 5
								2-Thr, 3-Thr
Oxo-Pro	1	172.7	-					

	2	54.2	6.55	dd, 10.0, 2.0	3, 5	3, 5	3, 1-Val	3, 5 2a-Sar, 2b-sar NMe
	3	41.8	2.32	d , 18.5	2, 5	2, 5	1	2, 5
			2.13	d, 13.0	2, 5	2, 5	1	2, 5
	4	208.0	-	-			-	
	5	53.7	3.83	d, 18.5	2, 3	2, 3	1, 2	2, 3
			3.90	dd, 18.5 12.0	2, 3	2, 3	1, 2	2, 3
Sar	1	166.4						
	2	51.28	2a, 4.54	d, 19.5	2b	2b, NMe	1, NMe, 1-Pro	2b, NMe, 2-
			2b, 3.95	d, 19.0	2a	2a, NMe	1, NMe, 1-Pro	oxopro 4-MeVal , 5- MeVal, NMe
	N-Me	34.7	2.88	S		2a, 2b	2, 1-Pro	2b, 2MeVal
MeVal	1	167.4	-	-				
	2	71.1	2.67	d, 8.5	3, 4, 5	3, 4, 5	1, 3, 4, 5, NMe	4, 5

3	26.8	2.60	d, 8.0	2, 4, 5	2, 4, 5	1, 3, 4, 5, NMe	4, 5
4	21.5	0.93	d, 6.0	2, 3	2, 3, 5	2, 3, 5	3
5	19.1	0.73	d, 6.0	2, 3	2, 3, 4	2, 3, 4	3
N-Me	39.0	2.91	S	-	2, 3	2, 1- Sar	2, 5, 2a-Sar, 2b- Sar

Chromophore

Position	δC	δH	J (Hz)	COSY	TOCSY	HMBC	NOESY
1	101.8	-					
2	147.3	-					
3	179.0	-					
4	113.4	-					
4a	144.9						
5	-						
5a	140.3						
6	127.6	-					
7	130.2	7.34	d, 8.0	8, 11	8, 11	5a, 9, 11-Me	11
8	126.0	7.56	d, 7.5	7, 11	7, 11	9a, 5a, 13	11

9	132.1	-					
9a	128.4	-					
10	-	-					
11	14.9	2.52	S	7, 8	7, 8	5a, 6, 7	7, 8
12	7.6	2.18	S	-	-	3, 4, 4a	-
13	166.0	-					
14	165.8	-					



Figure S53. <sup>1H</sup>-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum Of Compound R2



Figure S54. <sup>13</sup> C NMR (125 MHz, CDCl<sub>3</sub>) Spectrum Of Compound R2



Figure S55. DEPT135&90 (125 MHz, CDCl<sub>3</sub>) Spectrum of Compound R2



Figure S56. Expansion of DEPT135 &90 (125 MHz, CDCl<sub>3</sub>) Spectrum of Compound R2



Figure S57. Expansion of DEPT135 &90 (125 MHz, CDCl<sub>3</sub>) Spectrum of Compound R2



Figure S58. COSY (500 MHz) Spectrum of Compound R2



Figure S59. DQF-COSY (500 MHz) Spectrum of Compound R2



Figure S60. HMBC (500 MHz) Spectrum Compound of R2



Figure S61. HSQC (500 MHz) Spectrum of Compound R2



Figure S62. TOCSY (500 MHz) Spectrum of Compound R2



Figure S63. NOESY (500 MHz) Spectrum of Compound R2



Figure S64. <sup>1</sup>H-NMR (500 MHz, CDCl<sub>3</sub>) Spectrum of Compound R3



Figure S65. DQF-COSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Compound R3



Figure S66. HMBC (500 MHz) Spectrum of Compound R3



Figure S67. HSQC (500 MHz) Spectrum of Compound R3



Figure S68. TOCSY (500 MHz, CDCl<sub>3</sub>) Spectrum of Compound R3



Figure S69. NOESY (500 MHz) Spectrum of Compound R3



Figure S70. MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)



Figure S71. Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (positive mode)



Figure S72. Expansion of MALDI-TOF MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Negative mode)



Figure S73. MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)



Figure S74. Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (positive mode)



Figure S75. Expansion of MALDI-TOF MS Spectrum of R2 (Molecular ion peak) (Negative mode)



Figure S76. MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (positive mode)



Figure S77. MALDI-TOF MS Spectrum of R3 (Molecular ion peak) (Negative mode)



Figure S78. MALDI-TOF MS Spectrum of Transitmycin (R1) (Positive mode)


Figure S79. MALDI-TOF MS Spectrum of Transitmycin (R1) (Negative mode)

Table S6. MALDI-TOF MS Spectral Fragmentation of Transitmycin (R1) (Positive mode)







Figure S80. MALDI-TOF MS Spectrum of R2 (Positive mode)



Figure S81. MALDI-TOF MS Spectrum of R2 (Negative mode)



Figure S82. MALDI-TOF MS Spectrum of R3 (Positive mode)



Figure S83. MALDI-TOF MS Spectrum of R3 (Negative mode)



Figure S84. QTRAP MS/MS Transitmycin (R1) (Molecular ion peak) (Positive mode)



Figure S85 QTRAP MS/MS Transitmycin (R1) (Molecular ion peak [M+H]<sup>2+</sup> (Positive mode)



Figure S86. QTRAP MS/MS of Transitmycin (R1) (Molecular ion peak ) (Negative mode)



Figure S87. QTRAP MS/MS of R2 (Molecular ion peak) ((Positive mode)



Figure S88. QTRAP MS/MS of R2 [M+H]<sup>2+</sup> ion peak (Positive mode)



Figure S 89. QTRAP MS/MS of R2 (Molecular ion peak (Positive mode)



Figure S90. QTRAP MS/MS of R3 Molecular ion peak (Positive mode)



Figure S91. QTRAP MS/MS of R3 (Molecular ion peak (Negative mode)



Figure S92. HR-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)



Figure S93. HR-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion Peak) (Positive mode)



Figure S94. HR-ESI-MS Spectrum of R2 (Positive mode)



Figure S95. HR-ESI-MS Spectrum of R2 (Molecular ion Peak) (Positive mode)



Figure S96. HR-ESI-MS Spectrum of R3 (Positive mode)



Figure S97. HR-ESI-MS Spectrum of R3 (Molecular ion Peak) (Positive mode)



Figure S98. LC-ESI-MS Spectrum of Transitmycin (R1) (Molecular ion peak) (Positive mode)



Figure S99. LC-ESI-MS Spectrum of Transitmycin (R1) (Positive mode)



Figure S100. LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)



Figure S101. LC-ESI-MS Spectrum of Trasitmycin (R1) (Positive mode)



Figure S102. LC-ESI-MS Spectrum of R2 (Positive mode)



Figure S103. LC-ESI-MS Spectrum of R2 (Molecular ion) (Positive mode)



Figure S104. LC-ESI-MS Spectrum of R3 (Positive mode)



Figure S105. LC-ESI-MS Spectrum of R3 (Positive mode)



Figure S106. EI-MS Spectrum of Transitmycin (R1) (Positive mode)



Figure S107. EI-MS Spectrum of (R1) (molecular ion peak) (Positive mode)



Figure S108. EI-MS Spectrum of (R2) (Positive mode)



Figure S109 EI-MS Spectrum of (R3) (Positive mode)



Figure S110. CHN analysis data of Transitmycin (R1), R2, R3



Figure S111. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (Negative mode)



Figure S112. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)



Figure S113. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode mode)


Figure S114. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)



Figure S115. 3200 QTRAP LC/MS/MS Spectrum of Transitmycin (R1) (positive mode)

#### STRUCTURAL CHARACTERISATION OF PRODUCT IONS OF [MS2] THE [M+NA]+ IONS OF TRANSITMYCIN a) TRANSITMYCIN (R1) OBTAINED BY b) (R1) OBTAINED BY QTRAP LCMS/MS [MS2] OF 1291.6]



**Figure S115 a-b** Structural characterisation of Transitmycin (R1) obtained by QTRAP LC-MS/MS. **b** Product ions [MS2] the [M+Na]+ ions Transitmycin (R1) obtained by QTRAP LCMS/MS [MS2] of 1291.6, 1291.6 [M+H]<sup>+</sup>, 1178.5 Loss of H-MeVal-OH, 1065.5 Loss of 2XH-MeVal, 994.2 Loss of Sar-2XH-MeVal-OH, 923.4 Loss of 2XSar-2XH-MeVal-OH, 851.3 Loss of 2XSar-2XH-MeVal-OH, 796.4 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH, 683.2 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-MeVal-OH, 657.5 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH, 639.4 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH (18), 518.3 Loss of H'-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro-Sar-MeVal-OH + Loss of H-Th-Val-Pro-Sar-MeVal-OH.

# Table S7a. Structural characterisation of Transitmycin (R1) obtained by QTRAP LCMS/MS

Product ions of [MS2] the [M+H] <sup>+</sup> ions of Transitmycin (R1) obtained by QTRAP LCMS/MS
[MS2] of 1269.7
$1269.7 = [M+H]^+$
1269.7-313.2 = 956.5 Loss of H-Oxo-Pro-Sar-MeVal-OH
1269.7-412.5 = 857.2 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH
1269.7-612.3 = 657.4 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Sar-MeVal-OH
1269.7-711.3 = 558.4 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Pro- Sar-MeVal-OH
1269.7-739.3 = 530.3 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Pro- Sar-MeVal-OH (-28)
1269.7-810.4 = 459.3 Loss of H-Val-Oxo-Pro-Sar-MeVal-OH + Loss of Val-Pro- Sar-MeVal-OH
1269.7-870.4 = 399.3 Loss of H-Val-Pro- Sar-MeVal-OH
1269.7-969.7 = 300.2 Loss of H-Pro- Sar-MeVal-OH
1269.7-1007.5 = 262.2 Loss of H-Pro- Val-Sar-OH
1269.7-1066.3 = 203.4 Loss of H-Sar-MeVal-OH
1269.7-1100.4 = 169.3 Loss of H-Pro-Sar-OH

Product ions of [MS2] the [M+Na] <sup>+</sup> ions of Transitmycin (R1) obtained by QTRAP LCMS/MS
[MS2] of 1291.6]
$1291.6 = [M+H]^+$
1291.6-113.1 = 1178.5 Loss of H-MeVal-OH
1291.6-226.1 = 1065.5 Loss of 2XH-MeVal
1291.6-297.4 = 994.2 Loss of Sar-2XH-MeVal-OH
1291.6-368.2 = 923.4 Loss of 2XSar-2XH-MeVal-OH
1291.6-440.3 = 851.3 Loss of 2XSar-2XH-MeVal-OH
1291.6-495.2 = 796.4 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH
1291.6- 608.4 = 683.2 Loss of H-Thr-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-MeVal-OH
1291.6- 634.1 = 657.5 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH
1291.6-652.2 = 639.4 Loss of H-Val-Pro- Sar-MeVal-OH + Loss of H-Pro- Sar-MeVal-OH (18)
1291.6-772.7 = 518.3 Loss of H`-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH
1291.6-772.7 = 518.3 Loss of H`-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH
1291.6-804.0 = 487.0 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32)
1291.6-848.3 = 443.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH (32)
1291.6-886.3 = 405.3 Loss of H-Val-OXO-Pro-Sar-MeVal-OH + Loss of H-Val-Pro- Sar-MeVal-OH
1291.6-957.2 = 334.4 Loss of H-Th-Val-Oxo-Pro-Sar-MeVal-OH + Loss of H-Th-Val-Pro- Sar-MeVal-OH

# Table S7b. Structural characterisation of Transitmycin (R1) obtained by QTRAP LCMS/MS

The Transitmycin A (3.0 mg) dissolved in 6N HCl (1 mL) and heated at 110 <sup>0</sup>C for 24 h. The solvent was removed under reduced pressure, and the resulting material was subjected to further derivatization. The hydrolysate mixture (3.5 mg) or the amino acid standards (0.5 mg) were dissolved in 0.1 mL of water and treated with 0.2 mL of 1% 1-fluoro-2,4-dinitrophenyl-5-Lalaninamide (FDAA) in acetone and 0.04 mL of 1.0 M sodium bicarbonate. The vials were heated at 50 <sup>o</sup>C for 90 min, and the contents after cooling at room temperature were neutralized with 1 N HCl. After degassing, an aliquot of the FDAA derivative was diluted in MeOH and purified by chromatography using a RP C-18 column (250 X 4.6 mm) and a linear gradient of acetonitrile and water containing 0.05% trifluoroacetic acid from 20:80 to 50:50 in 20 min and then isocratic. The flow rate was 1 mL/min, and the absorbance detection was at 340 nm. The chromatogram was compared with those of amino acid standards treated in the same conditions. The above same procedure for other two compounds B and C were done.



Figure S116. Hydrolysis of Amino Acid Residue of Transitmycin (R1), R2, R3

#### Figure S117a. HPLC analysis of standard L-FDAA-D/L-Valine



Figure S117 b. HPLC analysis of standard L-FDAA-D-Valine



Figure S117c. HPLC analysis of standard L-FDAA-L-Valine



Figure S118 (a). HPLC analysis of standard L-FDAA-D/L-Proline







Figure S118c. HPLC analysis of standard L-FDAA-L-Proline



### Figure S119a. HPLC analysis of standard L-FDAA-D/L-Threonine



Figure S119b. HPLC analysis of standard L-FDAA-D-Threonine





### Figure S120a.HPLC analysis of standard L-FDAA-D/L-N-Methyl Valine





Figure S120c.HPLC analysis of standard L-FDAA-D-N-Methyl Valine









Figure S121C. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of Transitmycin (R1)



Figure S121b. HPLC analysis of standard L-FDAA-L-Valine

Figure 122a.HPLC analysis of standard L-FDAA-D-Valine



Figure S122b. HPLC analysis of standard L-FDAA-L-Valine



Figure S122c. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R2





Figure S123b.HPLC analysis of standard L-FDAA-L-Valine



### Figure S123c. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3





Figure S124. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of (R2)



Figure S125. HPLC Analysis of L-FDAA Derivatives of acid hydrolysates of R3

Ausing a side	HPLC retention times Marfey's derivatives of standard amino acids		HPLC retention time Marfey derivatives of	Assignment
Amino acids	D	L	Transitmycin R2	
Threonine	15.682	13.987	14.000	L
Proline	17.035	16.519	16.529 & 16.960	D & L
Valine	21.244	19.248	19.300	L
N-methyl valine	22.089	20.814	21.255	L

# Table 8a. Analysis of L-FDAA derivates of acid hydrolysate of R2 by HPLC

Table 8b. Analysis of L-FDAA derivatives of acid hydrolysate of R3 by HPLC

	HPLC retention times Marfey's derivatives of standard amino acids		HPLC retention time Marfeyderivatives of	Assignment
Amino acids	D	L	Transitmycin R3	
Threonine	15.682	13.987	13.988	L
Proline	17.035	16.519	16.512 & 17.000	D&L
Valine	21.244	19.248	19.235	L
N-methyl valine	22.089	20.814	21.242	L



Figure S126. ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)



Figure S127. ESI- MS Spectrum of Marfey's Derivatives of Transitmycin (R1) (Positive mode)



Figure S128. LCMS analysis of Standard L-FDAA-D-Proline (Positive mode)



Figure S129. LCMS analysis of Standard L-FDAA-D-Proline (Negative mode)



Figure S130 LCMS analysis of Standard L-FDAA-L-Proline (Positive mode)



Figure S131. LCMS analysis of Standard L-FDAA-L-Proline (Negative mode)



Figure S132. LCMS analysis of Standard L-FDAA-D/L-Proline (Positive mode)



Figure S133. LCMS analysis of Standard L-FDAA-D/L-Proline (Negative mode)



Figure S134.. LCMS analysis of Standard L-FDAA-D-Valine (Positive mode)



Figure S135. LCMS analysis of Standard L-FDAA-D-Valine (Negative mode)



Figure S136. LCMS analysis of Standard L-FDAA-L-Valine (Positive mode)



Figure S137. LCMS analysis of Standard L-FDAA-L-Valine (Negative mode)



Figure S138. LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)



Figure S139. LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)



Figure S140. LCMS analysis of Standard L-FDAA-D/L-Valine (Positive mode)



Figure S141. LCMS analysis of Standard L-FDAA-D/L-Valine (Negative mode)



Figure 142. LCMS analysis of Standard L-FDAA-D-Threonine (Positive mode)



Figure S143. LCMS analysis of Standard L-FDAA-D-Threonine (Negative mode)



Figure S144. LCMS analysis of Standard L-FDAA-D/L Threonine (Positive mode)



Figure 145. LCMS analysis of Standard L-FDAA-D/L Threonine (Negative mode)


Figure S146. LCMS analysis of Standard L-FDAA-D/L N-Methyl valine (Positive mode)



Figure S147. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)



Figure S148. LCMS analysis of Standard L-FDAA-L N-Methyl valine (Positive mode)



Figure S149. LCMS analysis of Standard L-FDAA-L- N-Methyl valine (Positive mode)



Figure S150. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)



Figure S151. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)



Figure S152. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Negative mode)



Figure S153. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)



Figure S154. LCMS analysis of Standard L-FDAA-L N-Methyl Valine (Positive mode)



Figure S155. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Positive mode)



Figure S156. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)



Figure S157. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)



Figure S158. LCMS analysis of Standard L-FDAA-D/L N-Methyl Valine (Negative mode)



Figure S159. LCMS analysis of L-FDAA derivatives of Transitmycin (R1) (Positive mode)



Figure S160. LCMS analysis of L-FDAA derivatives of R1 (Negative mode)



Figure S161. LCMS analysis of L-FDAA derivatives of R3 (Positive mode)

	LCMS retention times Marfey's derivatives of standard amino acids		HPLC retention time	M+H]+	[M-H]-	Assignment
Amino acids			Marfey derivatives of	m/z	m/z	
	D	L	acid hydrolysate of Transitmycin R1	Positive mode	Negative mode	
Threonine	9.90	13.50	13.73	372.13	370.13	L
Proline	15.16	14.31	14.23 &15.36	366.13	363.07	D&L
Valine	19.65	17.65	18.02	370.13	368.07	L
N-methyl valine	20.33	19.25	19.96	384.20	382.20	L

## Table S9a. Analysis of L-FDAA derivates of acid hydrolysate of Transitmycin R2 by HPLCMS

 Table S9b. Analysis of L-FDAA derivates of acid hydrolysate of R3 by HPLCMS

	LCMS retention times Marfey's derivatives of standard amino acids		HPLC retention time	[M+H]+	[M-H]-	Assignment
Amino acids			Marfey derivatives of acid	m/z	m/z	
	D minutes	L minutes	hydrolysate of R3 minutes	Positive mode	Negative mode	
Threonine	9.90	13.50	12.45	372.13	370.13	L
Proline	15.16	14.31	14.25	366.13	363.07	D & L
Valine	19.65	17.65	17.49	370.13	368.07	L
N-methyl valine	20.33	19.25	19.93	384.20	382.20	L

### Table S10. Physico-chemical properties of R2

Colour:	Red colour amorphous powder
Yield:	100 mg, 10%
m.p:	250-252°C

TLC: Rf = 0.6 (Ethyl acetate/Methanol, 95:5)

 $[\alpha]_D^{25}$ : -24° (c = 0.2, MeOH)

Solubility: Soluble in Chloroform, Dichloromethane, Ethyl acetate, Methanol, Ethanol, Acetonitrile, DMSO, water.Insoluble in Hexane.

UV: (MeOH)  $\lambda_{\text{max}}$ , (log  $\varepsilon$ ) 205, (1.25), 240 (0.63), 425 (0.39), 442 (0.42) nm

CD: [MeOH, [nm], (mdeg)]:  $\lambda_{max}$ , ( $\Delta\epsilon$ ) 195 (+8.8), 210 (-22.0), 240 (+4.3) nm

IR: (KBr),  $v_{\text{max}}$ = 3436, 2961, 2924, 2853, 1744, 1650, 1565, 1415, 1204, 1140, 1045, 1019 cm<sup>-1</sup>

HRESI-MS: m/z(pos.ions) 650.3413 [M+2H]<sup>+2</sup>, 1277.8245 [M + Na]<sup>+</sup> 1293.8735 [M + K]<sup>+</sup>

 $C_{62}H_{86}N_{12}O_{16}Na \; [M+Na]^+ \; calc. \; 1277.61824, \; \; found. \; 1277.8245$ 



MALDI-TOF-MS: m/z (pos.ions) 1279.94914 [M + Na+2H]<sup>+</sup> m/z (neg.ions) 1255.38052[M-H]<sup>-</sup> [M + Na+2H]<sup>+</sup> calc. 1279.63424, found. 1279.94914

- LCESI-MS: m/z (pos.ions) 1277.8245 [M + Na]<sup>+</sup> C<sub>62</sub>H<sub>86</sub>N<sub>12</sub>O<sub>16</sub>Na [M + Na]<sup>+</sup> calc. 1277.61824, found. 1277.8245
- EI-MS: (70 ev) *m/z* (pos.ions: 739.9827, 616.9573, 547.2778, 434.2708, 391.5160, 200.1560, 146.7755, 11.2256
- CHN: Anal. calcd for  $C_{62}H_{86}N_{12}O_{16}C$ , 59.32; H, 6.90; N, 13.39. Found: C, 61.05; H, 7.25; N, 11.32.



### Table S11. Physico-chemical properties of R3

Colour:	Orange colour	amorphous	powder	(50	mg)
---------	---------------	-----------	--------	-----	-----

Yield: 50 mg, 5%

m.p: 220-222°C

R<sub>f:</sub> 0.3 (Ethyl acetate-Methanol 95:5)

Solubility: Soluble in Chloroform, Dichloromethane, Ethyl acetateMethanol, Ethanol, Acetonitrile, DMSO, water. Insoluble in Hexane

 $[\alpha]_D^{25}$ : -27 ° (c = 0.2, MeOH)

UV (MeOH)  $\lambda_{\text{ma x}}(\log \varepsilon) 206 (1.90), 240 (0.69) 424 (0.191), 442.2 (0.19) \text{ nm}$ 

CD: [MeOH,[nm], (mdeg) ] $\lambda_{max}(\Delta \epsilon)$  195 (+24.0), 210 (-21.5), 241 (+1.7)

IR:(KBr), $v_{max}$  3415, 2957, 2924, 2853, 1745, 1642, 1583, 1464, 1384, 1193, 1093, 1078 cm<sup>-1</sup>.

HRESI-MS: m/z (pos.ions) 663.4698 [M+2H]<sup>+2</sup>, 1271.7159 [M + H]<sup>+</sup>

 $C_{62}H_{86}N_{12}O_{17}\ [M+H]^+\ calc.\ 1277.6312,\ \ found.\ 1271.7159$ 

MALDI-TOF-MS: m/z (pos.ions) 1292.24097 [M + Na]<sup>+</sup> m/z(neg.ions) 1268.48582[M-H]<sup>-</sup>

 $C_{62}H_{86}N_{12}O_{17}Na [M + Na]^+$  calc. 1293.61316 found. 1292.24097

LCESI-MS: m/z (pos.ions) 1277.6149 [M-OH+Na+H]<sup>+</sup>C<sub>62</sub>H<sub>85</sub>N<sub>12</sub>O<sub>16</sub> [M – OH+Na+H]<sup>+</sup> calc. 1277.61416, found. 1277.6149

- EI-MS: (70 ev) *m/z* (pos.ions): 98, 956.7713, 900, 9470, 859.8045, 771.227, 708.0386, 562.4686, 515.1946, 446.3967, 351.8868, 1\230.2476, 94.2476
- CHN: Anal. calcd for  $C_{62}H_{86}N_{12}O_{17}C$ , 58.57; H, 6.82; N, 13.22.

Found: C, 58.75; H, 7.13; N, 11.59.

Culture No.	Isoniazid	Rifampicin	Kanamycin	Ofloxacin
1-49	S	S	S	S
50	R	S	S	S
51	R	S	S	S
52	S	R	S	S
53	R	S	S	S
54	S	S	S	R
55	R	S	S	S
56	R	S	S	R
57	R	S	S	S
58	R	S	S	S
59	R	S	R	R
60	R	R	R	S
61	S	S	R	S
62	R	S	S	R
63	R	S	S	R
64	R	S	R	R
65	R	S	S	S

Supplementary Table 12: Drug resistant profile of the clinical isolates of *Mycobacterium tuberculosis* used to determine the anti TB activity of Transitmycin. R: Resistant; S: Susceptible. The drug resistant profile was determined by LJ based Proportion sensitivity method.

66	R	S	S	R
67	R	S	S	R
68	R	S	R	R
69	S	S	S	R
70	S	S	S	R
71	R	S	S	S
72	R	S	S	R
73	R	R	S	S
74	R	S	S	S
75	R	R	S	S
76	R	R	R	S
77	R	R	S	R
78	R	R	S	R
79	R	S	S	S
80	R	S	S	R
81	R	S	S	S
82	R	R	S	S
83	R	R	S	S
84	R	R	S	R
85	R	R	S	S
86	R	R	S	R

87	S	R	S	R
88	R	R	S	S
89	R	R	S	S
90	S	R	S	R
91	S	S	S	R
92	R	R	S	S
93	R	R	S	R
94	S	R	S	R
95	R	S	S	R
96	R	R	S	S
97	R	S	S	R

## S - Table 13. Anti-HIV activity of Transitmycin on various HIV-1 subtypes

HIV-1 subtype	l subtype (in µg/mL)					EC50 value (µMI)	
	0 0.01 0.1 1 10		10				
SUB A	4624.7 ± 348.34	2600.31 ± 212.27	1413±84.36	$116.00 \pm 13.61$	133.32 ± 13.33	0.263	
SUB B	9123.78 ± 495.29	8419.48 ± 549.73	7470.78 ± 3208.54	4222.52 ± 138.79	1693.95±35.38	2.347	
SUB C	11652.5 ± 1339.97	10962.821±729.96	11005.35±144.9	3435.69 ± 75.80	578.46 ± 65.77	2.167	
SUB D	$10170.22 \pm 1572$	10761.7 ± 576.85	7405.783±303.46	1339.49±287.06	306.53±27.43	0.447	
SUB E	3976.34 ± 68.35	3726.96±590.53	2120.49±155.83	970.25 ±38.08	258.84 ± 3.87	0.78	
SUB A/C	5871.52 ± 51.10	5562.45±396.06	4654.15 ±262.26	589.52 ± 133.80	154.45 ±30.20	0.685	
NEV RES	3325.76 ± 259.01	3636.10 ±743.95	3278.46 ±329.16	627.37 ±69.58	341.00 ±7.88	0.771	
AZT RES	3031.83 ± 821.87	3040.03±703.81	2213.102±48.17	1066.38 ± 17.34	786.32 ±37.46	0.388	

# Acknowledgements for Characterisation of Transitmycin

The Chairman, NMR Research Centre, IISC, Bangalore

Dr.A.Mohan, Mr.Venkatesan, Department of Chemistry, IIT Madras

Dr.M.S.Moni, Dr.C. Baby, Mr. R. Bhaskar, SAIF IIT Madras for 2D NMR analysis

Prof. T. Pradeep, AnanyaBaksi, DST Unit of Nano science IIT Madras for QTRAP LC/MS/MS

Prof. T. Pradeep, Mr.Kamalesh, Mr. E. Sundaraj, DST Unit of Nano Science IIT Madras for MALDI-TOF

Mrs.Sunita Prakash, Molecular Biophysics Department, IISC Bangalore for ESI-MS/MS, MALDI TOF-MS/MS

Mrs.Santha, Mr.Thankarasu, Department of Chemistry IIT Madras for Q-TOF-ESI-MS

Mr. Sankar, SAIF, IIT Madras for IR, EI-MS

The Head, SAIF CDRI, Luknow for LC-ESI-MS

Mr.Muralidhar, SID IISC Bangalore LC-ESI-MS

Prof.Anju Chanda, Mr. T.Saravanan, Department of Biotech IIT Madras for Optical Rotation measurement

Mrs.S.Srividya, Department of Chemistry, IIT Madras.

Dr. P.M.Sivakumar, Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu , 600036, India

Dr. Veluchamy Prabhawathi Department of Biotechnology, Indian Institute of Technology Madras, Chennai, Tamilnadu, 600036, India

#### **Supplementary References:**

- Xiaoling Wang, Jioji Tabudravu Mostafa Ezzat Rateb, Krystal Joan Annand, Zhiwei Qin, Marcel Jaspars, Zixin Deng, Yi Yband Hai Deng, Identification and characterization of the actinomycin G gene cluster in Streptomyces iakyrus, *Mol. BioSyst.*, 9, 1286–1289. (2013).
- Rebecca H. Wills, Peter B. O'Connor Structural Characterization of Actinomycin D Using Multiple Ion Isolation and Electron Induced Dissociation J. Am. Soc. Mass Spectrom. 25:186Y19, (2014).
- 3. IvanaCrnovci c, Siamak Semsary, Joachim Vater and Ullrich Keller, Biosynthetic rivalry of o-aminophenol-carboxylic acids initiates production of hemi-actinomycins in Streptomyces antibioticus, RSC Adv., **4**, 5065 (2014).
- 4. JoachimVater, Ivana Crnovčić, Siamak Semsary and Ullrich Keller MALDI-TOF mass spectrometry, an efficient technique for in situ detection and characterization of actinomycins, J. Mass Spectrom., **49**, 210–222 (2014).
- Collisional Activation Decomposition of Actinomycins Using Tandem Mass Spectrometry J. Roboz, E. Nieves and J. F. Holland M. McCamish, C. Smith, BIOMEDICAL AND ENVIRONMENTAL MASS SPECTROMETRY, VOL. 16, 67-70 (1988).
- A. B. Mauger, W. A. Thomas, NMR Studies of Actinomycins Varying at the Proline Sites, ORGANIC MAGNETIC RESONANCE, VOL. 17, NO. 3(1981).
- 7. Darren Thomas, Michael Morris, Jonathan M. Curtis and Robert K. Boyd, Fragmentation Mechanisms of Protonated Actinomycins and Their Use in Structural Determination of Unknown Analogues, JOURNAL OF MASS SPECTROMETRY, **VOL. 30**, 1111-1125 (1995).
- 8. Jens Bitzer, Martin Streibel, Hans-Jörg Langer, Stephanie Grond, First Y-Type Actinomycins from *Streptomyces*with Divergent Structure-Activity Relationships for Antibacterial and Cytotoxic Properties, *Org. Biomol. Chem.*, *7*, 444–450. (2009).
- Caixia Chen, Fuhang Song, QianWang, Wael M. Abdel-Mageed, HuiGuo, Chengzhang Fu & WeiyuanHou & Huanqin Dai & Xueting Liu & Na Yang & FengXie & Ke Yu & Ruxian Chen & Lixin Zhang, A marine-derived Streptomyces sp. MS449 produces high yield of actinomycin X2 and actinomycin D with potent anti-tuberculosis activity, Appl Microbiol Biotechnol 95:919–927, (2012).

- 10. Shigehiro Kamitori and FusaoTakusagawa' Multiple Binding Modes of Anticancer Drug Actinomycin D:X-ray, Molecular Modeling, and Spectroscopic Studies of d (GAAGCTTC)2-Actinomycin D Complexes and Its HostDNA, *J. Am. Chem. SOC.*,**116**, 41544165, (1994).
- 11. JensBitzer, Victoria Gesheva, and Axel Zeeck, Actinomycins with Altered Threonine Units in the â-Peptidolactone, J. Nat. Prod., 69, 1153-1157, (2006).
- 12. Xiufang Zhang, Xuewei Ye, Weiyun Chai, Xiao-Yuan Lian, and Zhizhen Zhang, New Metabolites and Bioactive Actinomycins from Marine-Derived Streptomyces sp. ZZ338, Mar. Drugs, **14**, 181, (2016).
- 13. Helmut Lackner, Isabel Bahner, Nobuharu Shigematsu Lewis K. Pannell, and Anthony B. Mauger, Structures of Five Components of the Actinomycin Z Complex from *Streptomyces fradiae*, Two of Which Contain 4-Chlorothreonine, *J. Nat. Prod*, *63*, 352-356, (2000).
- 14. . F. Conti, P. DeSantis Conformation of Acitinomycin D Nature, Vol. 227, 19, (1970).